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IX. Abstract Antibiotic resistant strains of bacteria are a serious threat to human health. With increasing antibiotic resistance in common human pathogens, fewer antibiotics remain effective. Staphylococcus aureus is a pathogenic bacterium of particular concern to human health as it has developed resistance to many of the currently used antibiotics leaving very few remaining as effective treatment. Alternatives to current conventional antibiotics are needed to allow for the continued treatment of bacterial infections. In addition, a deeper understanding of the characteristics of antibiotic resistant bacteria is needed to allow for an increased ability to properly treat them and to potentially identify targetable changes. To address these two issues, this study aimed at investigating antibacterial activity of an anti-scabies permethrin cream, and examining the lipidomics, proteomics, cell wall thickness and whole-cell surface charge of methicillin sensitive S. aureus (MSSA) and methicillin resistant S. aureus (MRSA). The permethrin cream was found to contain both 5% permethrin and 0.3% formaldehyde and so both were tested alone and in combination for antibacterial activity against MSSA and MRSA. This was done using antimicrobial susceptibility experiments and time-kill assays with viable counts determined using a drop plate method. In addition, any effect of permethrin on cell morphology was investigated using scanning electron microscopy. While permethrin was found to have little effect on bacterial growth and morphology, formaldehyde was found to be capable of inhibiting the growth of both MSSA and MRSA at concentrations found in the permethrin cream as well as four times lower (0.07%) and at 0 hours. Formaldehyde therefore represents a potential alternative treatment for infections with antibiotic resistant bacteria. But for it to be used in this manner the risks associated with it will need to be investigated as there is a lack of literature relating to the effect of dermal application of formaldehyde in humans. The lipid species and proteins present in each strain of MSSA and MRSA were identified using ultra-performance liquid chromatography – mass spectrometry and their relative abundances were compared. Cells were also embedded into resin, sectioned using an ultramicrotome and imaged by scanning transmission electron microscopy to measure and compare cell wall thickness between strains. Finally, the whole-cell surface charge was determined and compared for each strain using a cytochrome c binding assay. Of the lipids identified, three were found to be present at a higher abundance in the MSSA group than the MRSA group including a diglycosyldiacylglycerol that plays a role in membrane stability and two lysyl-phosphatidylglycerols that contribute a positive charge to the membrane. Of the proteins identified eight were present at significantly different abundances between MSSA and MRSA. Four were present at a higher abundance in the MSSA group and four at a higher abundance in the MRSA group. These proteins played roles in protein biosynthesis, amino acid metabolism and carbohydrate metabolism. Eighteen proteins were found to be present at significantly different abundances between the individual strains. They played roles in protein biosynthesis, 
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amino acid metabolism, carbohydrate metabolism and as virulence factors. No difference was found between the thickness of the cell wall between the MSSA group and MRSA group but there were differences between the individual strains. No difference in whole-cell charge was observed between the strains. The differences in cell wall thickness, lipid abundance and protein abundance found in these strains are unique to this study. The results presented here show that permethrin is a poor inhibitor of bacterial growth but formaldehyde rapidly kills MSSA and MRSA and therefore may serve as an alternative to conventional antibiotics. Additionally, individual strains of MSSA and MRSA were shown to be able to differ from each other beyond the characteristic antibiotic resistance changes. Continued work on this would benefit from examining a wider range of strains and including mutant strains and/or antibiotic challenge to understand how MRSA can change beyond the well characterised expression of penicillin binding protein 2A. This would allow for a deeper understanding into the functioning of S. aureus cells and this can be used to better develop treatments for infections with antibiotic resistant strains of bacteria. 
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1. Introduction Antibiotic resistance is a serious threat in the clinic with a variety of infectious bacteria possessing resistance to commonly used antibiotics. Of particular concern is methicillin resistant Staphylococcus aureus (MRSA). MRSA has developed resistance to antibiotics including penicillin and methicillin with some strains having developed further resistances to daptomycin and vancomycin, complicating treatment further (1,2). This rapid increase in antibiotic resistance has outpaced the development of new antibiotic compounds and threatens to end the golden age of antibiotics we are currently living in and begin the post-antibiotic era. As such, research has been directed towards developing novel treatments outside of traditional antibiotics as well as towards a deeper understanding of the changes that occur in bacteria after they develop antibiotic resistance. Antibiotic resistant strains of S. aureus can also be found as a secondary infection with scabies. Scabies is an infectious skin disease caused by mites and is treated with permethrin. Permethrin kills scabies mites by forcing their voltage-gated sodium channels (VGSCs) to remain open leading to prolonged depolarisation, paralysis and death (3). A permethrin cream with a formaldehyde preservative has been implicated as being capable of decreasing infection with antibiotic resistant bacteria but whether permethrin itself possesses antibacterial properties is unknown (4). Formaldehyde possesses strong genotoxic activity against bacteria (5) so it may have been responsible for the observed decrease in infection. More research into permethrin and formaldehyde could lead to their use as alternatives to antibiotics for treating staphylococcal infections. The cell wall, cell membrane and virulence factors of S. aureus are important components necessary for its survival and ability to infect humans. The cell wall of S. 
aureus consists of a layer of peptidoglycan and is responsible for maintaining cell shape and resisting osmotic pressure (6). The cell membrane in S. aureus is a phospholipid bilayer that acts as a selectively permeable barrier and protects the cell from the entry of harmful substances such as antibiotics (7). Virulence factors are proteins that help the bacterium in establishing an infection, damaging the host and interfering with host immunity (8). These cellular components represent current and potential targets for antibiotics and other novel treatments. A deeper understanding of them and how they change in both methicillin sensitive S. aureus (MSSA) and MRSA is essential for the continued development of effective antibacterial treatment. A brief review of antibiotics, scabies and permethrin, bacterial cell components and the development of antibiotic resistance in S. aureus is included to provide the background knowledge necessary to understand the work conducted. 
1.1 Bacteria and Antibiotics 
1.1.1 Antibiotics Antibiotics are a class of compounds that can inhibit the growth of or kill bacteria. The first and most famous antibiotic to be discovered was penicillin. However, even before the discovery of penicillin, other non-antibiotic antimicrobials had been discovered and used. In 1910, arsphenamine was introduced to treat syphilis and trypanosomiasis. It 
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was discovered in 1909 by Sahachiro Hata and was the most used antimicrobial drug until the introduction of antibiotics in the 1940s (9). Penicillin (Figure 1A) was discovered by Alexander Fleming in 1928 after he noticed that an old culture plate (contaminated with Penicillium notatum) grew a mould that prevented the growth of S. aureus. He experimented with different moulds to better understand this effect and determined that not all mould produced the antimicrobial component detected on this plate. While he failed to isolate the active molecule itself, he named it penicillin. In 1940 Howard Florey and Ernst Chain published a paper that described a purification technique for penicillin and in 1945 penicillin was available for limited use in human treatment (10). Even before the discovery of penicillin by Alexander Fleming in 1928, mould had been recognised as having medicinal properties. In ancient Egypt, Greece, China and Rome topical applications of mouldy bread were used to treat infections. In 1870, Sir John Scott Burdon-Sanderson described mould covered culture fluid as being capable of inhibiting bacterial growth and in 1871 Joseph Lister conducted experiments using 
Penicillium glaucium showing an antibacterial effect (10). While other scientists may have discovered the antibacterial properties of mould it was only when Fleming’s work brought more attention to these properties that the golden age of antibiotics began. Penicillin and all members of the penicillin class of antibiotics are derivatives of 6- aminopenicillanic acid with a β-lactam ring structure responsible for their antimicrobial activity. They work by attaching to enzymes called penicillin binding proteins (PBPs) thereby inhibiting peptidoglycan cross link formation in bacterial cell wall synthesis. Both modification to PBPs and the presence of enzymes that can cleave the β-lactam ring structure are known resistance methods found in bacteria. In fact, by 1957, more than 80% of hospitals reported the presence of penicillin resistant strains of S. aureus. It was this resistance that prompted more research into alternative antibiotics. By the end of the 1950s semi-synthesis around the 6-aminopenicillanic acid core of penicillins presented a new class of penicillinase resistant penicillins including methicillin (Figure 1B). Prior to this in 1943, streptomycin was isolated by Selman Waksman from the soil bacterium Streptomyces griseus. Streptomycin was the first antibiotic available for use against tuberculosis. Waksman also established that as many as 50% of actinomycetes in soil were capable of antimicrobial activity (9). This thereby directed research towards the discovery of naturally produced antibiotics in soil bacteria. 
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Figure 1: Structure of antibiotics used against S. aureus. A) Penicillin G. B) Methicillin. C) Vancomycin. D) Daptomycin. 
1.1.2 Antibiotic Resistance Bacteria that have become capable of growing even in the presence of antibiotics are said to be antibiotic resistant. Whether a bacterial species is considered sensitive to or resistant to an antibiotic depends on the minimum inhibitory concentration (MIC) breakpoint. The MIC breakpoint is the concentration of an antibiotic that represents the barrier between resistance and sensitivity. If the concentration needed to kill the bacteria is less than or equal to the MIC breakpoint, the bacteria is considered susceptible to that antibiotic. If the amount required is higher, it is considered resistant (11). The MIC breakpoint is set based on the highest safe level of the drug in human serum when administered (12). The rate of antibiotic resistance development currently exceeds the rate at which new drugs are developed and this threatens to end the golden age of antibiotics and begin the post-antibiotic era. This would have a ubiquitous effect on medical procedures as they all rely on the use of antibiotics to manage infections. Many antibiotics are derived from natural products that are used as defence mechanisms by bacteria against other bacteria. Therefore, it is only expected that resistance to these products would also be found naturally in the environment as otherwise the bacteria that produce these molecules as a defence mechanism would also be killed by them. However, the increased use of these natural products as therapeutic agents has created a stronger selection pressure than would normally be seen and has thus promoted the increased development and growth of antibiotic resistant bacteria (Figure 2). This is thought to 
A B 
C D 
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occur both due to random mutation and horizontal gene transfer (13). One such bacterial species that has readily developed resistance and become a significant problem in clinical settings is S. aureus.  
 
Figure 2: Spread of antibiotic resistant bacteria by natural selection. 
1.1.3 Staphylococcus aureus 
Staphylococcus aureus is a Gram-positive cocci bacterium that can be found as a common commensal on human skin and in the human nasal cavity. There are also reports of S. aureus being present in the oropharynx. Around 30% of the population live asymptomatically colonised with S. aureus. However, S. aureus can also act as a pathogenic bacteria and is the cause of a variety of human infectious diseases that range from skin infections like impetigo to more serious conditions like osteomyelitis and endocarditis (14). Infections with S. aureus are typically treated with antibiotics but the increased development and spread of antibiotic resistant strains has made treatment increasingly difficult. 
Page | 5  
Methicillin resistant S. aureus is a widely studied antibiotic resistant strain that is of clinical significance. As many as 60% of clinically isolated strains of S. aureus have been found to be resistant to methicillin (6). 
1.1.3.1 Methicillin Resistant Staphylococcus aureus There exist two kinds of MRSA infections that are characterised by the origin of the infection. The first is called healthcare-associated MRSA (HA-MRSA) and occurs when someone is infected with MRSA in a healthcare setting (such as a hospital or nursing home). This is typically as a result of procedures like surgery or the use of catheters that compromise the body or provide a portal of entry, allowing the bacteria into the body. This is made more dangerous by the individual usually being immunocompromised. HA-MRSA is associated with blood stream infections and pneumonia. The second kind  of MRSA infection occurs in the wider community and usually affects healthy individuals that have not recently been in contact with a healthcare facility. This is called community-associated MRSA (CA-MRSA). This form of MRSA infection is associated with skin and soft tissue infections and is usually spread by skin contact. CA-MRSA infections were initially defined by a set of criteria. This excluded healthcare risks such as a prolonged hospital stay or need for haemodialysis. Furthermore, it included hospitalised patients if the bacterium was isolated within 48 hours of admission (Table 1). CA-MRSA strains have also been identified by molecular characteristics such as pulsed field gel electrophoresis (PFGE) profile, multilocus sequence type (MLST), staphylococcal protein A (spa) type and staphylococcal chromosomal cassette mec (SCCmec) type (15). HA-MRSA and CA-MRSA are genetically distinct with HA-MRSA resistant to multiple antibiotic classes but CA-MRSA only resistant to β-lactams and macrolides (16). HA- MRSA was initially the most common form of MRSA infection however this has changed in recent years with CA-MRSA becoming more common than HA-MRSA in some regions including in Australia (17) and in children in some regions of the United States (18). Furthermore, CA-MRSA accounts for 70% of all community-associated infections with staphylococci and 74% of all S. aureus caused pneumonia at Texas Children's Hospital (19). Cases of HA-MRSA strains infecting people in the community and CA-MRSA infecting hospital patients have however begun to obscure the line between CA-MRSA and HA-MRSA and have made many of the methods of distinguishing the two invalid. 
Table 1: Characteristics of healthcare-associated and community-associated methicillin resistant S. aureus.  
Type of 
MRSA 
Location Acquired Associated Diseases Healthcare- Associated Obtained in healthcare settings including nursing homes and hospitals Bloodstream infections Pneumonia Community- Associated Obtained in the wider community or within 48 hours of admission to a hospital Skin and soft tissue infections 
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Penicillin was discovered in 1928 but it was not introduced for medical use until 1944. Once used in the clinic however, it allowed for the management of serious bacterial infections that were previously unresponsive to treatment, including those of Staphylococci. In 1946, shortly after its introduction, the first penicillin resistant S. 
aureus was isolated (20). These penicillin resistant strains were resistant due to the acquisition of the blaZ gene carried on Tn552-like transposons or the remnants of these transposons. The blaZ gene codes for a protein called β-lactamase (also known as 
penicillinase) that inhibits the action of penicillin by hydrolysing the β-lactam ring structure (Figure 3). Penicillin resistance is defined by an MIC of ≥ 0.25 µg/mL (21). After penicillin resistance was identified in S. aureus, an alternative antibiotic treatment was needed. This came in the form of methicillin which was introduced in 1959 to treat penicillin resistant strains. However, much like with penicillin, the indiscriminate use of this antibiotic promoted the development and spread of resistance and in 1961 (only two years after its introduction) there were cases of strains of methicillin resistant S. 
aureus reported in England. Other countries soon reported similar resistances (22). 
Methicillin resistance is defined by an MIC of oxacillin ≥ 4 µg/mL (23). 
S. aureus gained resistance to methicillin by acquisition of the mecA gene present on the mobile genetic element SCCmec. There exist 11 types of SCCmec (from I to XI) of varying sizes, ranging from 21 kb to 67 kb. However, in all cases SCCmec is integrated into the S. 
aureus genome at the same point, at an attB integration site sequence at the 3’ end of  the orfX gene (24). The mecA gene codes for a protein called penicillin binding protein 2A (PBP2A) that is able to cross-link peptidoglycan after the native penicillin binding 
proteins are inactivated by β-lactam antibiotics (such as methicillin) (Figure 3). While β- lactam antibiotics like methicillin can bind to PBP2A, a distorted active site means that the antibiotics cannot inactivate the protein thereby rendering their antibacterial activity ineffective (25,26). 
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Figure 3: Antibiotic action of penicillin and methicillin against S. aureus and resistance mechanisms used by S. aureus against penicillin and methicillin. The acquisition of the SCCmec and the subsequent evolution of MRSA is something that is still being investigated. Two hypotheses have been proposed to explain the emergence and spread of MRSA in hospitals and the community. The first is the single- clone theory that suggests all MRSA clones have a common MSSA ancestor. The second, the multi-clone theory, suggests that the SCCmec containing mecA was introduced several times to different ancestral MSSA strains (27). The multi-clone theory is better supported by the literature. For example, in Enright et al. (22) several SCCmec types were identified in different strains of MRSA. Furthermore, there are more genetic differences between MRSA strains than would be expected if they all originated from a single MSSA strain. This supports the independent development of MRSA from multiple different MSSA strains. The origin of the SCCmec found in MRSA is unknown but it is found in other species of coagulase negative staphylococci (named such to distinguish from the coagulase producing S. aureus). It is speculated that SCCmec is capable of being transferred 
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between staphylococci species and the literature considers the most likely origin to be from a coagulase negative staphylococci (28). Two of the more likely candidates are 
Staphylococcus sciuri and more recently Staphylococcus fleuretti (24). Vancomycin (Figure 1C) was considered one of the last resort antibiotics for treating MRSA, but even this has been rendered ineffective against certain strains of MRSA that have acquired vancomycin resistance. Initially isolates of MRSA with reduced susceptibility to vancomycin were reported in 1997. This was either as vancomycin insensitive S. aureus (VISA) or heterogeneous VISA (hVISA). VISA refers to strains with reduced susceptibility in the entire population whereas hVISA refers to populations with acceptable MIC of vancomycin that also contain a small subpopulation (around one in every 105–106 cells) that have reduced susceptibility to vancomycin (2). The first vancomycin resistant strain of S. aureus was reported in the US in 2002. Vancomycin 
resistance is defined as an MIC ≥ 16 µg/mL and is found in strains of MRSA due to the acquisition of the vanA operon. This operon is present on the Tn1546 transposon and originally came from the vancomycin resistant enterococci (VRE) conjugative plasmid (29,30). The vanA operon confers vancomycin resistance by interfering with the synthesis of the cell wall to remove the vancomycin binding site (Figure 4). The cell wall in Gram- positive bacteria is made up of cross linked peptidoglycan strands. These strands are made up of glycan chains of N-acetylglucosamine (NAG) and N-acetylmuramic acid (NAM), cross linked by glycine bridges. Vancomycin interferes with peptidoglycan synthesis by binding to the final D-Ala-D-Ala residue of the newly synthesised peptide and disrupting downstream assembly. However, in VISA the proteins VanA, VanH, VanX and VanY coded by the vanA operon remove the vancomycin binding site. This is done in two major steps. In the first, the dipeptide D-Ala-D-Ala peptidoglycan precursors are hydrolysed by VanX (a D,D-dipeptidase) and VanY (a D,D-carboxylpeptidase). In the second major step VanA (a ligase that catalyses ester bond formation) and VanH (a dehydrogenase that forms D-Lac by reduction of pyruvate) synthesise D-Ala-D-Lac (that vancomycin cannot bind) to replace the D-Ala-D-Ala residue (29). 
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Figure 4: Antibiotic action of vancomycin against S. aureus and resistance mechanisms used by S. aureus against vancomycin. Daptomycin (Figure 1D) is a cyclic peptide antibiotic. It has been approved for use against S. aureus and is considered a mainstay of anti-MRSA therapy. Daptomycin’s mode of action requires calcium to form a complex with it. This complex behaves as a cationic peptide and oligomerises to form micelles. These micelles then penetrate the cell wall and insert into the lipid membrane by binding to phosphatidylglycerol. The micelles thereby disrupt the membrane causing depolarisation, permeabilisation and ion leakage (11). An MIC breakpoint that determines resistance has not been determined yet for daptomycin in S. aureus but a level for susceptibility has been set. An MIC of < 1 mg/L is considered susceptible for bacteria and an MIC > 1 mg/L is considered non-susceptible. There are several potential explanations for daptomycin non-susceptibility. These include a more positively charged membrane, changes to membrane fluidity and alanylation of teichoic acids (Figure 5) (1). The year of discovery of penicillin, methicillin, vancomycin and daptomycin can be seen in Figure 6 as can the year of the first reported development of resistance to these antibiotics in S. aureus. 
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Figure 5: Antibiotic action of daptomycin against S. aureus and resistance mechanisms used by S. aureus against daptomycin. 
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Figure 6: Timeline of development of antibiotic resistance in S. aureus. 
1.1.3.2 Strains of Methicillin Resistant Staphylococcus aureus There exist many different strains of MRSA that are found in different parts of the world and in different environments. As mentioned above, different strains can be characterised by their antimicrobial susceptibility, DNA fragment patterns upon PFGE, 
spa gene typing, carriage of Panton-Valentine leucocidin (PVL) genes, MLST, and the type of SCCmec element carried (31). In this study the QLD1, AUS-2, USA300, SWP and WA-1 MRSA strains were investigated (Table 2). The QLD1 strain was first identified in 2000 in Queensland. It is PVL positive and despite its high prevalence in Australia it has rarely been seen on other continents. Infections with the QLD1 strain are associated with severe infections such as skin and soft tissue infections and necrotising pneumonia (31). Its MLST is ST93, its spa type is t202 and it carries the SCCmec type IV (32). The AUS-2 strain of MRSA is a HA-MRSA strain and one of the first multiresistant MRSA strains in Australia arising in 1976 (33). Its MLST is ST239, its spa type is t037 and it carries the SCCmec type III (34,35). The USA300 strain originated in the community, is not related to healthcare-associated strains and nearly always carries PVL genes. Its MLST is ST8, its spa type is t008 and it carries the SCCmec type IV. The USA300 strain has also since become a common cause of healthcare-associated infections, blurring the line between CA-MRSA and HA-MRSA (18,32,36). In addition, it carries the arginine catabolic mobile element (ACME) as well as phenol soluble modulins (PSMs). It is these and PVL that have been proposed to 
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contribute to its pathogenicity (37). The SWP strain was first reported in Australia, New Zealand and Western Samoa, is a common community-associated strain in Australia, is PVL positive (38) and associated with abscess formation, bacteraemia and necrotising pneumonia (39). Its MLST is ST30, its spa type is t019 and it carries the SCCmec type IV (32). The first non-multiresistant MRSA strain was observed in the 1990s in Aboriginal communities in Western Australia. This became known as the WA-1 strain (39). The WA-1 strain of MRSA is PVL negative, its MLST is ST1, its spa type is t128 and carries the SCCmec type IV (32). 
Table 2: Strains of methicillin resistant S. aureus and associated characteristics.  
Strain MLST1 PVL2 Spa3 Type SCCmec4 Type QLD1 ST93 + t202 Type IV Aus-2 ST239 - t037 Type III USA300 ST8 + t008 Type IV SWP ST30 + t019 Type IV WA-1 ST1 - t128 Type IV 1Multilocus Sequence Type 2Panton-Valentine Leucocidin Production 3Staphylococcal Protein A 4Staphylococcal Cassette Chromosome mec 
1.2 Scabies and Permethrin Scabies is an infectious skin disease caused by the mite Sarcoptes scabiei that, after infecting the host, burrow into the skin causing itching. Scabies infections may be accompanied with secondary bacterial infections including Group A Streptococci and S. 
aureus. These secondary bacterial infections can lead to diseases such as impetigo and endocarditis. Permethrin is a synthetic pyrethroid that is used as the preferred treatment of scabies infections (3). Its structure is shown in Figure 7. Permethrin works against scabies mites by targeting their voltage-gated sodium channels and preventing the channels from transitioning from activated to inactivated states. This disruption forces an influx of sodium ions leading to prolonged depolarisation, paralysis and death of the mite (40).  
Figure 7: Structure of permethrin. The VGSCs of insects consists of a voltage sensor domain comprised of four transmembrane helices and an ion conducting pore module made up of two helices. These are connected by a helical linker. When modelling the structure of the VGSC, it was found that the helices of two separate domains in the protein form a hydrophobic pocket facing the lipid bilayer. It is within this pocket that permethrin (and other pyrethroids) bind to exert their insecticidal effect (41). 
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As a pyrethroid, permethrin is toxic to insects but significantly less so to humans. There are a few potential explanations for this. These include lipid solubility favouring entry through the insect cuticle and not favouring entry in mammals, a difference in the detoxification processes in insects and humans and permethrin potentially being more effective at lower temperatures such as those found in insects. There is also substantial evidence to suggest that differences in the sodium channel sequences play a role in the difference between toxicity (41). The key amino acid residue occurs at position 918 in the VGSC protein and is a methionine in insects but isoleucine in mammals. When these isoleucine residues are replaced with a methionine in rats, the rats become more sensitive to the effects of pyrethroids, implicating this amino acid residue as being key to the toxicity of pyrethroids (42). 
1.3 Formaldehyde Formaldehyde is the simplest aldehyde and was first synthesised in 1855. It exists as a colourless gas with a strong odour at room temperature. Its structure is shown in Figure 8. Formaldehyde is used for a variety of roles including in the manufacture of particle board, plywood and other wooden furniture products. It is also used in embalming and as a preservative in cosmetics and medicinal creams (5). It is commonly used as an aqueous solution of 37% formaldehyde (particularly when used as a preservative) called formalin (43). Its known genotoxic activity against bacteria and fungi is responsible for its successful use as a preservative. Formaldehyde can bind to DNA and proteins causing DNA-DNA cross-links, DNA-protein cross-links, irreversible formaldehyde adducts as well as other forms of DNA and protein damage (44,45).  
Figure 8: Structure of formaldehyde. Formaldehyde is effective against S. aureus with an MIC of 156 mg/L (0.02%) (46). It is effective even against antibiotic resistant strains with no reports of formaldehyde resistant S. aureus in the literature. Formaldehyde has also been used to treat bacterial infections as the antibiotic methenamine. Methenamine is an antibiotic that was used to treat urinary tract infections but has since become a “forgotten drug”. Its antibacterial mode of action involves releasing formaldehyde in acidic environments. It has bactericidal activity when used at concentrations greater than 25 µg/mL (47). In addition to its wide use in manufacturing and as a preservative, formaldehyde is also an important cellular metabolite in bacteria. Methanotrophic and methylotrophic bacteria produce formaldehyde during oxidation of hydrocarbons such as methane and methanol (44). As a result, some bacteria have developed methods to survive the toxic effects of formaldehyde. This can be through enzymatic breakdown to less toxic products such as in Amycolatopsis methanolica and Mycobacterium gastri in which formaldehyde dismutase breaks formaldehyde down into formate and methanol. Despite this resistance mechanism, these bacteria are still susceptible to formaldehyde at concentrations above 0.8 mM (48). Resistance to formaldehyde can also be due to the 
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presence of NAD dependent formaldehyde dehydrogenases. These can be found in some members of the family Enterobacteriaceae as well as in some Pseudomonas species including methanol-utilizing methylotrophic bacteria like Pseudomonas methanica and some other formaldehyde-utilizing bacteria like Pseudomonas aeruginosa. In 
Enterobacteriaceae, resistance developed as a result of plasmid acquisition while in 
Pseudomonas, resistance is chromosomally located. Strains of Escherichia coli with formaldehyde resistance have also been identified and it has been generally accepted that formaldehyde resistance is most often found in Gram-negative bacteria (49). No S. 
aureus strains have been reported to be resistant to formaldehyde. 
1.4 Bacterial Cell Components 
1.4.1 Cell Wall The bacterial cell wall is a key component of bacteria. Its roles include maintaining cell shape and allowing the cell to resist osmotic pressure. The structure of the cell wall differs between Gram-positive bacteria and Gram-negative bacteria (Figure 9). Gram- positive bacteria have a thicker peptidoglycan layer and teichoic acids in their cell wall whereas Gram-negative bacteria have a thinner peptidoglycan layer and an outer membrane exterior to the peptidoglycan layer that contains lipopolysaccharides. The peptidoglycan layer of Gram-positive bacterial cell walls makes up the majority of the layer and provides structural stability to the cell wall (6). The peptidoglycan layer is made up of glycan strands that are polymerised and cross linked together by the collective action of more than 10 proteins. These glycan strands are made up of alternating NAG and NAM (Figure 10) residues. In addition to NAG and NAM, the glycan strand also includes a stem and a bridge component. In S. aureus the stem component is the pentapeptide, L-Ala-D-iso-Gln-L-Lys-D-Ala-D-Ala and the bridge component is a pentaglycyl segment. The disaccharide NAG and NAM are polymerised into the glycan 
chain (connected by a β(1–4) glycosidic bond) and the chain is then cross-linked to other chains between the N-terminus of the terminal glycine of the pentaglycyl segment attached to one stem, and the D-Ala of a neighbouring pentapeptide stem (50). Penicillin binding proteins catalyse both the strand polymerisation (transglycosylation) and cross-linking (transpeptidation) steps in cell wall synthesis (51). 
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Figure 9: Bacterial cell wall structure. A) Gram-positive bacteria. B) Gram-negative bacteria. Glycan strands are modified after their synthesis and this modification is different depending on the bacterial species. One such modification found in S. aureus is O- acetylation. O-acetylation of NAM residues but not NAG residues has been observed in S. 
aureus. The gene OatA was first identified in S. aureus and is responsible for synthesis of the O-acetyltransferase that catalyses the O-acetylation reaction of peptidoglycan. This modification contributes to the resistance of pathogenic Gram-positive bacteria to lysozyme. The teichoic acids present in the cell wall and the cross linking of the peptidoglycan layer also contribute to lysozyme resistance (52). The amount of cross- linking found in the strands varies depending on the bacteria with staphylococci generally having a high proportion of cross-linking (80%-90%). The staphylococcal peptidoglycan layer ranges from 20 nm to 40 nm in thickness (6,53). Glycan strands vary in chain length in different species but this variation does not impact cell wall thickness. In S. aureus the length of glycan strands is on average 18 disaccharide units with a majority being between 3-10 disaccharide units and about 10-15% being more than 26 disaccharide units (54). 
A B 
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Figure 10: Structure of N-acetylglucosamine and N-acetylmuramic acid. Teichoic acids are found in the cell wall of Gram-positive bacteria, and in S. aureus it is estimated that every ninth peptidoglycan NAM residue possesses an attached teichoic acid. Teichoic acids are anionic glycopolymers that extend beyond the peptidoglycan layer (55). The structure of a wall teichoic acid (WTA) can be broken down into two main components. The first is a disaccharide linkage unit. The disaccharide linkage unit contains an N-acetylmannosamine (β1→4) N-acetylglucosamine-1-phosphate (disaccharide) with one to three glycerol-3-phosphate (G3P) units attached to the C4 hydroxyl of the N-acetylmannosamine residue (linkage unit). The phosphate of the linkage unit is covalently attached to the C6 hydroxyl of a peptidoglycan NAM by a phosphodiester bond. The second component is the main chain polymer of phosphodiester linked polyol repeats. These repeats extend from the G3P end of the disaccharide linkage unit (56,57). In S. aureus the polyol units are poly(ribitol- phosphate) repeats. The structure of S. aureus WTAs is summarised in Figure 11 (58). Teichoic acids play a variety of important roles in Gram-positive bacteria. They assist in host interaction, defining cell shape, antibiotic resistance and help protect the cell from turgor pressure (6,58). In addition to teichoic acids, the cell wall also contains surface proteins. These proteins can be covalently linked to the peptidoglycan or non-covalently bound to cell wall polymers (54).    
 
Figure 11: Structure of the cell wall teichoic acid of S. aureus. R=H, α-GlcNAc, β-GlcNAc, D-Ala. 
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1.4.2 Cell Membrane The bacterial cell membrane is a phospholipid bilayer and an essential component of the cell. It acts as a selectively permeable barrier in order to maintain appropriate concentrations of nutrients and waste inside the cell. It is also crucial for proton motive force, generation of ATP, protection from the entry of harmful substances and cell to cell communication as it is the site of these processes. In addition to phospholipids the cell membrane also contains membrane associated proteins that assist with these roles (7). The bacterial cell membrane is made up of a variety of different species of lipids, including phospholipids and glycolipids. Some of the lipids found in the membrane of S. 
aureus include phosphatidylglycerols (PG), lysyl-phosphatidylglycerols (Lys-PG) monoglycosyldiacylglycerols (MGDG), diglycosyldiacylglycerols (DGDG) and cardiolipins (CL) (Figure 12).  
Figure 12: Structure of bacterial membrane lipids. 
1.4.2.1 Membrane Lipid Synthesis The first step in bacterial membrane lipid synthesis is the type II fatty acid biosynthetic pathway which takes place in the cytoplasm. This pathway is summarised in Figure 13. The first step involves the action of Acetyl-CoA carboxylase (ACC) that converts Acetyl- CoA to Malonyl-CoA with biotin as a cofactor. Next the malonyl group is transferred to the acyl-carrier protein (ACP) by FabD (a malonyl translocase) forming malonyl-ACP. FabH then condenses another Acyl-CoA with malonyl-ACP to form the first β-ketoacyl- ACP intermediate of the fatty acid synthase II pathway. Straight and branched chain fatty acids are then produced as part of the elongation step of the fatty acid synthase II pathway. The branched chains are introduced during the initiation phase by FabH enzymes. In S. aureus the FabH enzyme prefers larger branched-chain substrates (59). Chain elongation is then carried out as four enzymatic reactions. At the end of these four 
steps, the growing acyl chain is advanced two carbons. First the β-ketoacyl-ACP 
intermediate is reduced by the FabG β-ketoreductase producing β-hydroxyacyl-ACP 
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which is then dehydrated by FabA or FabZ to enoyl-ACP. The cycle must then be pulled to completion by an enoyl-reductase (FabI). A new round of elongation is then initiated by an elongation condensing enzyme, either FabF or FabB and the cycle continues (59). Staphylococcal phospholipid synthesis then starts by the acylation of G3P with the fatty acids. PlsX transfers the acyl group from the long chain acyl-ACP produced during the elongation step described above to inorganic phosphate to form the acylphosphate intermediate. PlsY then uses the acyl-phosphate as a substrate to acylate G3P to 1-acyl- G3P. A second fatty acid is then transferred from acyl-ACP to 1-acyl-G3P by the action of PlsC to create phosphatidic acid. Phosphatidic acid is the universal bacterial phospholipid precursor. The phosphatidate cytidylyltransferase Cds catalyses the synthesis of CDP-diacylglycerol from phosphatidic acid and cytidine triphosphate. PgsA then catalyses the generation of phosphatidylglycerolphosphate by replacing cytidine monophosphate with glycerolphosphate. Finally, phosphatidylglycerolphosphate is dephosphorylated by a phosphatidylglycerophosphatase to create phosphatidylglycerol. The phosphatidylglycerol can then be modified to create other membrane phospholipids. It can be aminoacylated with an L-lysine group from a lysyl-tRNA by the multipeptide resistance factor (MprF) to create lysyl-phosphatidylglycerol (60). It can also be converted into cardiolipin by the CL synthases Cls1 and Cls2. These enzymes condense two PG molecules into one CL and glycerol (61). Alternatively, phosphatidic acid can be dephosphorylated to form diacylglycerol (DAG) as part of the synthesis of MGDG and DGDG. After dephosphorylation of phosphatidic acid to DAG, glycosyl transferases then transfer a glycosyl residue to the DAG to form MGDG. The MGDG is then used as a substrate and a second glycosyl residue can be added to form DGDG (62). One enzyme is responsible for the first glycosylation of the diacylglycerol, creating MGDG and another for the second glycosylation, creating DGDG (63). The glycosyl transferase activity seen in S. aureus is limited to the cytoplasm side of the membrane with the final DGDG product being translocated to the extracellular side (62). The enzymes responsible for the formation of MGDG and DGDG in S. aureus are part of the GT28 family (64). 
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Figure 13: Cell membrane lipid synthesis pathway. 
1.4.2.2 Role of Membrane Lipid Species Bacterial cell membrane lipids play important roles in antibiotic resistance and this role varies based on lipid class (Table 3). Phosphatidylglycerol is a phospholipid that contains two acyl chains, esterified to a glycerol which is then in turn bonded to a head group containing a phosphate. Due to the negative phosphate and no other compensating positive charges, PG contributes an overall negative charge to the bacterial membrane (65). Furthermore, PG functions as a stabiliser and destabiliser by strong electrostatic interactions between charged species. This is believed to play an important role in controlling interactions between membrane peptides and proteins (66). Lysyl-phosphatidylglycerol is a PG that has been aminoacylated with an L-lysine group from a lysyl-tRNA by the MprF protein. The MprF protein consists of a hydrophilic C- terminal domain and hydrophobic N-terminal domain. The C-terminal domain is responsible for lysinilation of PG in the inner leaflet of the bacterial membrane whereas the N-terminal domain is responsible for translocation of Lys-PG across the membrane. Lys-PG production has been shown to decrease S. aureus susceptibility to cationic antimicrobial peptides (CAMPs) by increasing cell surface charge (60). Lys-PG has also been shown to play a role in cell cycle regulation by regulating DNA replication initiation. This is through the DNA replication initiator protein DnaA which is inhibited by PG and CL promoting the release of ATP from it. Lys-PG however, counteracts this interaction and this could be due to a decrease in the negative charge of the membrane 
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or interruption of acidic phospholipid cluster domains as a result of increased presence of Lys-PG (67). Cardiolipin is made up of four acyl chains and subsequently has a large number of potential species (68). Once S. aureus reaches the stationary phase, most of the PG found in its membrane is converted to CL. As mentioned above, this is done by the CL synthases Cls1 and Cls2 by condensing two PG molecules to create one CL and glycerol (61). Cls2 primarily synthesises cardiolipin under normal conditions whereas Cls1 does so under acid stress (60). Cardiolipins can stabilise liposomes against osmotic stress and has been shown to be unnecessary for growth under high salt conditions but essential for long term survival in that environment (69). Cardiolipins have also been shown to contribute to resistance to daptomycin by preventing membrane permeabilisation (70). Monoglycosyldiacylglycerols and diglycosyldiacylglycerols have been shown to be responsible for the stability and fluidity of the cell membrane by their relative proportion. This is due to MGDG being non-bilayer forming whereas DGDG is bilayer forming (63). Living organisms need to be able to synthesise bilayer and non-bilayer forming lipids and adjust their relative ratios in order to respond to the effects of external triggering events. Monoglycosyldiacylglycerol and diglycosyldiacylglycerol 
provide this function. In addition, the βGlc(1→6)βGlc-DAG serves as a membrane anchor for lipoteichoic acids in Gram-positive bacteria including S. aureus (62). Generally, at neutral pH the membrane of S. aureus is made up of approximately 55% PG, 40% Lys-PG, and 5% CL (71). However, the phospholipid composition of the membrane can be changed in response to changes in growth phase as well as changes to external stimuli such as osmolarity, pH and temperature (69). This is done to change the properties of the membrane in order to help the cell survive. One such alteration can be made to the relative abundances of PG and Lys-PG. Phosphatidylglycerol is negatively charged whereas Lys-PG is positively charged and one can be made from the other by the action of enzymes. Doing so results in an increase of one or the other making the membrane more negatively or positively charged. This can help bacteria resist the action of antibiotics such as CAMPs. As CAMPs are positively charged an increase in Lys- PG and decrease in PG leads to an increase in the membrane charge which helps to repel CAMPs. Bacteria resistant to CAMPs have been found to have a higher proportion of Lys- PG in their membranes and an mprF deficient mutant was found to be highly sensitive to CAMPs (16,72). The method of upregulating Lys-PG is first triggered by CAMPs activating a sensor histidine kinase of the ApsSR regulon. This then leads to the upregulation of mprF expression leading to an increase in the MprF protein product that catalyses the production of Lys-PG from PG as mentioned above (71). 
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Table 3: Lipid classes present in the bacterial cell membrane, their role in the cell and their role in antibiotic resistance.  
Lipid Class Role in Cell Functioning Role in Antibiotic 
Resistance Phosphatidylglycerol Contributes negative charge to membrane. Functions as stabiliser and destabiliser by electrostatic interactions between charged species. 
Increases susceptibility to positively charged molecules such as CAMPs. 
Lysyl-Phosphatidylglycerol Contributes positive charge to membrane. Regulates DNA replication initiation through DNA replication initiator protein DnaA. 
Decreases susceptibility to positively charged molecules such as CAMPs. 
Cardiolipin Stabilises liposomes against osmotic stress. Essential for long term survival in high salt conditions. 
Contribute to daptomycin resistance by preventing membrane permeabilisation. Monoglycosyldiacylglycerol Responsible for the stability and fluidity of the cell membrane. Non-bilayer forming. 
May play a role in affecting the permeability of the cell to antibiotics. Diglycosyldiacylglycerol Responsible for the stability and fluidity of the cell membrane. Bilayer forming. 
May play a role in affecting the permeability of the cell to antibiotics.  
1.4.3 Virulence Factors The success of S. aureus as a pathogen is in part due to its extensive range of virulence factors. These virulence factors often possess more than one pathogenesis function and there are often multiple virulence factors with the same function. This versatility and redundancy contributes to S. aureus’ success as a pathogen (73). Some of the common virulence factors found in S. aureus include PSMs, α-toxin, protein A, PVL, staphylococcal enterotoxins (SE), staphyloxanthin, ACME, coagulase, toxic shock syndrome toxin-1, exfoliative toxins and haemolysins. The function of S. aureus virulence factors can be broken down into three main groups. These are the adhesins that allow bacteria to attach to human tissue, the toxins that cause tissue damage and the immunomodulators that interfere with host immunity (Table 4) (8). Panton-Valentine leucocidin is a bicomponent toxin made up of the two subunits LukS and LukF which are encoded by lukS-PV and lukF-PV respectively. It can be found in both MSSA and MRSA but is absent in most of the predominant HA-MRSA strains (74). Panton-Valentine leucocidin is a pore forming toxin that targets immune system cells such as neutrophils and monocytes. It also possesses pro-inflammatory effects. In order 
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to lyse the cell, the LukS component must bind to the human complement receptors C5aR and C5L2. This allows for LukF to dock and for the two subunits to oligomerise into a pore, lysing the cell (75). Phenol-soluble modulins are a family of amphipathic α-helical peptides. They have cytolytic activity against a variety of cells including neutrophils and erythrocytes (74). Phenol-soluble modulins are grouped by size and charge with PSMαs being shorter (20- 
25 amino acids) and PSMβs being larger (43-45 amino acids). PSMαs have a neutral or 
positive charge while PSMβs have a negative charge. PSMαs are more cytolytic and can 
trigger the inflammatory response through recruitment of neutrophils. PSMβs are less cytolytic but have been implicated in the spread of biofilms. As PSMs are coded by genes in the core genome rather than in mobile genetic elements, they are found in nearly all strains of S. aureus (75). Staphylococcal enterotoxins, also known as superantigens, are a group of 21 toxins designated SE-A to SE-U. They exert their effect by binding to MHC class II receptors on T-cells. This results in hyperstimulation and leads to rapid proliferation and massive cytokine release. This can lead to food poisoning and toxic shock syndrome (76). Toxic shock syndrome toxin-1 is another superantigenic toxin similar to staphylococcal enterotoxins. It is coded by the tst gene and serves as a major virulence factor in toxic shock syndrome (77). There are three exfoliative toxins in S. aureus called exfoliative toxin A, B and D. Exfoliative toxins act as proteases that cleave desmoglein 1 that connects epidermal cells. As a result, these toxins are associated with exfoliation of the epidermis. This is done without necrolysis or inflammation (77). Exfoliative toxins have also been implicated in staphylococcal scalded-skin syndrome (78). There are three main haemolysins found in S. aureus. These are α-haemolysin, β- 
haemolysin and γ-haemolysin. Both α- and γ-haemolysins are pore forming toxins that 
target a variety of human cells. α-haemolysin causes the destruction of epithelial cells, 
erythrocytes, monocytes and fibroblasts (79) while γ-haemolysin causes the destruction 
of neutrophils, monocytes and macrophages (80). β-haemolysin is not a pore-forming toxin but rather a neutral sphingomyelinase that hydrolyses sphingomyelin causing lysis of red blood cells (80). Protein A is a cell wall anchored protein expressed on nearly all strains of S. aureus. It is encoded by the spa gene and binds to the Fc region of IgG antibodies and to the Fab of Variable Heavy 3 idiotype B-cell receptors (75). By binding IgG in this way, protein A impairs the host response in phagocytosis and clearing of S. aureus. It has also been shown to initiate the pro-inflammatory cascade in the airway (74). Protein A binding to B-cells also induces rapid activation and expansion which is followed by apoptotic cell death (75). In these ways protein A is able to contribute to impairment of the host defence system that assists in S. aureus colonisation. Staphyloxanthin is the pigment responsible for the golden colour associated with S. 
aureus. Its role as a virulence factor is as an antioxidant to protect the cell from the reactive oxygen species generated by the host immune system (81). Therefore, unlike 
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the toxins described above, staphyloxanthin contributes to virulence by protecting the bacterial cell from the host and allowing for colonisation and spread rather than by targeting the host directly. The ACME is another virulence factor that contributes to virulence by assisting with colonisation rather than by targeting host cells. It is a 30.9 kb segment of DNA unique to the USA300 MRSA strain. It includes a cluster of arc genes that encode an arginine deiminase pathway and the oligopeptide permease operon (79). The arginine deiminase pathway can convert L-arginine to carbon dioxide, ATP, and ammonia (82). It is thought that this contributes to S. aureus colonisation by ammonification of the acidic skin environment (74). Coagulases, also contribute to S. aureus virulence by assisting in colonisation and evasion of the immune system rather than by targeting host cells. There are two coagulases in S. aureus that contribute to its virulence. These are named coagulase (Coa) and von Willebrand factor binding protein (vWbp) (83). During infection, both coagulases trigger the cleavage of fibrinogen to fibrin (84). It is believed that the fibrin is then able to coat the surface of S. aureus thereby allowing it to evade the opsonophagocytic clearance of the host immune system (83). 
Table 4: Virulence factors present in S. aureus.  
Virulence Factor Group Function Panton-Valentine Leucocidin Toxin Pore forming toxin that targets neutrophils and monocytes. Phenol-Soluble Modulin Toxin Cytolytic activity against neutrophils and erythrocytes. Staphylococcal Enterotoxin Toxin Bind to MHC class II receptors on T- cells causing rapid proliferation and massive cytokine release. Toxic Shock Syndrome Toxin-1 Toxin Major virulence factor in toxic shock syndrome. Exfoliative Toxin Toxin Protease that cleave desmoglein 1 that connects epidermal cells. Haemolysin Toxin Pore forming toxin that causes destruction of epithelial cells, erythrocytes, monocytes, fibroblasts, neutrophils and macrophages. Protein A Immunomodulator Cell wall anchored protein that binds to IgG antibodies, impairing host response in phagocytosis. Staphyloxanthin Immunomodulator Protects cell from reactive oxygen species produced by the host immune system. Arginine Catabolic Mobile Element Immunomodulator Contributes to colonisation by ammonification of the acidic skin environment. 
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Coagulase Immunomodulator Trigger cleavage of fibrinogen to fibrin that coats cell surface allowing evasion of opsonophagocytic clearance by the host immune system.  
1.5 Project Aims Antibiotic resistant strains of bacteria continue to develop and present a considerable threat to human health. To combat this, alternative treatments to conventional antibiotics need to be developed. In addition, further insights into the characteristics of antibiotic resistant strains are required to better understand how resistance develops and to potentially identify targetable changes. Therefore, there were two main aims of this project. The first aim was to determine whether permethrin or some other component of a permethrin cream possessed antibacterial activity responsible for the prior observations in Whitehall et al. (4) where anti-scabies treatment with a permethrin cream was capable of treating antibiotic resistant bacterial skin infections. In doing so a new antibacterial for use against antibiotic resistant bacteria could be identified. The second aim was to investigate and compare the properties of MSSA with clinically relevant strains of MRSA, including prominent Australian strains. This was done with a focus on the ultrastructure (cell wall, cell membrane and surface charge) and the physiology (lipid and protein profile) of the strains. 
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2. Materials and Methods 
2.1 Bacterial Strains and Culture Conditions Five methicillin sensitive and five methicillin resistant strains of Staphylococcus aureus were obtained from Dr Iain Gosbell (Liverpool Hospital, NSW, Australia) and were used throughout the study. The five methicillin sensitive strains used were referred to as MSSA 1, MSSA 2, MSSA 4, MSSA 6 and MSSA 8. The names and identities of the methicillin resistant strains are summarised in Table 5 (33). 
Table 5: Characteristics of methicillin resistant strains of S. aureus used in the experiments.  
Name Strain Type 
(HA/CA)* 
Origin Resistance Pattern MRSA 1 QLD1 CA-MRSA Australia Typically no additional resistances (susceptible to non-β-lactam classes of antimicrobials) MRSA 2 AUS-2 HA-MRSA Australia Macrolides/Lincosamides Tetracyclines Trimethoprim/sulfamethoxazole Gentamicin Fluoroquinolones MRSA 8 USA300 CA-MRSA USA Macrolides/Lincosamides Fluoroquinolones (variable) MRSA 9 SWP CA-MRSA New Zealand Typically no additional resistances MRSA 13 WA-1 CA-MRSA Australia Typically no additional resistances Macrolides/Lincosamides variable Fusidic acid variable *Healthcare-Associated/Community-Associated Luria-Bertani (LB) agar and Mueller-Hinton Broth (MHB) were purchased from Difco Laboratories (Detroit, MI, United States) and prepared as per manufacturer’s instructions for use in culturing of the S. aureus strains. Prior to use in the experiments, each strain of MSSA and MRSA were streaked onto LB agar and incubated overnight (19-20 hours) at 35 ± 2 °C in a Binder Drying and Heating Chamber Model ED 115 (Tuttlingen, Germany). After overnight incubation, plate grown samples were either used as is or 2-3 plate grown colonies were suspended in MHB to OD595 0.09 (≈1x108 colony forming unit/mL (CFU/mL) matching a 0.5 McFarland turbidity standard) using a SPECTROstar Nano spectrophotometer (BMG Labtech, Ortenberg, Germany). These cells were then diluted tenfold in MHB to 1x107 CFU/mL for use in the experiments. This mixture is referred to as the bacterial inoculum throughout the thesis. The volumes of the bacterial inoculum used in the experiments corresponded to 0.5x105 CFU/mL. 
2.2 In vitro Antimicrobial Testing The effect of permethrin on the growth of S. aureus cells was tested by exposing each strain to four concentrations of permethrin. These were two-fold concentrations and included the concentration found in the permethrin cream. Similarly, the effect of formaldehyde on the growth of S. aureus cells was tested by exposing each strain to four 
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concentrations of formaldehyde that included the concentration of formaldehyde present in the same cream. Finally, the effect of both permethrin and formaldehyde at the concentration present in the permethrin cream on the growth of S. aureus cells was tested. 
2.2.1 Permethrin Exposure Permethrin was obtained from Sigma (Castle Hill, NSW, Australia) as a mixture of cis and trans isomers and was diluted in MHB to make a stock for use in the experiments. As permethrin does not readily dissolve in water, the MHB and permethrin mixture was placed into an ultrasonic cleaner (Scientifix, Cheltenham, VIC, Australia) at 37 °C to assist in the dissolving process. This was done for 10 minutes or until the solution became homogeneous. Five microliters of the bacterial inoculum, as prepared above, was added to each of 1.25%, 2.5%, 5% and 10% permethrin in separate wells of a 96-
well croplate at a final volume of 100 µL. A positive control containing cells in MHB without permethrin was also included. The microplates were incubated on a benchtop orbital shaker (Thermo Fisher Scientific, Scoresby, VIC, Australia) for 20 hours at 35 °C and 100 rpm. After incubation viable counts were determined by a drop plate method as described below. Each experiment was repeated three times independently. 
2.2.2 Formaldehyde Exposure Formaldehyde solution was obtained from Electron Microscopy Sciences (Hatfield, PA, United States) and diluted in MHB to make a stock for use in the experiments. Ten microliters of the bacterial inoculum were added to each of 0.07%, 0.15%, 0.3% and 
0.6% formaldehyde in separate Eppendorf tubes at a final volume of 200 µL. A positive control containing cells in MHB without formaldehyde was also included. Initially the experiment was conducted in a microplate as was done for permethrin exposure but it was observed that there was no growth in any condition, including the control. This was most likely due to fumes emitted from the higher formaldehyde concentrations and therefore to prevent interference in future experiments, any experiments conducted with formaldehyde were done so in separate Eppendorf tubes. The Eppendorf tubes containing cells were incubated on a benchtop orbital shaker for 20 hours at 35 °C and 100 rpm. After incubation viable counts were determined by a drop plate method as described below. Each experiment was repeated three times independently. 
2.2.3 Permethrin and Formaldehyde Combination Exposure To determine whether permethrin and formaldehyde work synergistically or antagonistically together against S. aureus, each strain was grown in the presence of a combination of permethrin and formaldehyde at the same concentrations as found in the permethrin cream. Ten microliters of the bacterial inoculum were dispensed into separate 1.5 mL Eppendorf tubes that contained 5% permethrin, 0.3% formaldehyde, a combination of 5% permethrin and 0.3% formaldehyde and MHB alone, each at a final 
volume of 200 µL. These tubes acted as the permethrin exposure, formaldehyde exposure, combination exposure and positive control respectively. Each tube was then incubated on a benchtop orbital shaker for 20 hours at 35 °C and 100 rpm. After incubation viable counts were determined by a drop plate method as described below. Each experiment was repeated three times independently. 
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2.2.4 Time-Kill Assay A time-kill assay was conducted to determine the time at which formaldehyde exerts its antibacterial effect on the ten strains of S. aureus as well as to determine if permethrin interferes with this antibacterial activity or not. The Eppendorf tubes were set up as was done for the permethrin and formaldehyde combination experiments and incubated on a benchtop orbital shaker at 35 °C and 100 rpm. Samples were taken at 0, 4, 8 and 24 hours post incubation and viable counts were determined as described below. Each experiment was repeated three times independently. 
2.2.5 Viable Counts Viable counts were determined using the drop plate method (modified from Miles, 
Misra & Irwin (85)). Each cell suspension was serially diluted tenfold and 10 µL of the appropriate dilutions were dispensed onto LB agar plates in triplicate. The plates were placed in an incubator overnight at 35 °C. After incubation the number of colonies were counted and the average CFU/mL calculated. Percent inhibition was then determined for the permethrin exposure, formaldehyde exposure and combination exposure experiments using the formula below. This was repeated for each experimental run and the average percent inhibition of all three experiments calculated. Bactericidal activity 
was defined as a decrease in growth of ≥ 99.9% (≥3log10 CFU/mL reduction). 
𝐶𝐶𝐶𝐶𝐶𝐶/𝑚𝑚𝑚𝑚 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 − 𝐶𝐶𝐶𝐶𝐶𝐶/𝑚𝑚𝑚𝑚 𝑇𝑇𝐶𝐶𝑇𝑇𝑇𝑇𝐶𝐶𝑇𝑇𝑇𝑇 % 𝐼𝐼𝐶𝐶ℎ𝑖𝑖𝑖𝑖𝑖𝑖𝐶𝐶𝑖𝑖𝐶𝐶𝐶𝐶 = ( 𝐶𝐶𝐶𝐶𝐶𝐶/𝑚𝑚𝑚𝑚 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 ) × 100   
2.2.6 Scanning Electron Microscopy To visualise any effect that permethrin had on the growth and morphology of S. aureus cells, each strain was grown in the presence of 5% permethrin, fixed by glutaraldehyde and dehydrated in an ethanol series for imaging by scanning electron microscopy (SEM). 
Cells were first exposed to permethrin by dispensing 10 µL of the bacterial inoculum into a 1.5 mL Eppendorf tube to a final volume of 200 µL along with 5% permethrin in MHB. A positive control containing cells in MHB without permethrin was also included. The tubes containing cells were then incubated on a benchtop orbital shaker for 20 hours at 35 °C and 100 rpm. After incubation for 20 hours, cells to be examined by SEM were then fixed and dehydrated. This was done by first centrifuging in a Beckman Coulter Microfuge 22R centrifuge (Lane Cove, NSW, Australia) at 9,000 rcf for 10 minutes to pellet cells. The supernatant was then removed and the cells washed in 0.1 M Na-phosphate buffer (pH 7.4). Na-phosphate buffer was made up by adding 0.1 M NaH2PO4 (VWR Chemicals, Tingalpa, QLD, Australia) to 0.1 M Na2HPO4 (Merck, Bayswater, VIC, Australia) till pH was 7.4. A wash step consisted of suspending the cell pellet in 200 µL 0.1 M Na- phosphate buffer, centrifuging at 9,000 rcf for 10 minutes and removing the supernatant. The wash step was repeated three times. Cells were then fixed by 
suspending in 200 µL of 2.5% glutaraldehyde (ProSci Tech, Kirwan, QLD, Australia) in 0.1 M Na-phosphate buffer and incubating overnight at 4 °C. Following overnight 
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incubation at 4 °C, cells were centrifuged at 9,000 rcf for 10 minutes and the supernatant removed. Cells were then again washed three times in 0.1 M Na-phosphate buffer before being dehydrated in an ethanol series. For this, cells were suspended in 
200 µL of ethanol (Chem-Supply, Gillman, SA, Australia), incubated at room temperature for 10 minutes and centrifuged at 9,000 rcf for 10 minutes before removing the supernatant. The ethanol dehydration series was conducted with 30%, 50%, 70%, 80%, 90% and then 100% ethanol. While suspended in 100% ethanol, the cells were incubated at room temperature for 1 hour. Five microliters of the final cell suspension in 100% ethanol was then transferred to a silica wafer for imaging by SEM. Cells were examined by SEM using a Zeiss Merlin FE-SEM (Oberkochen, Germany). This was done under low vacuum with a beam strength of 1 kV, an aperture of 30 µm and with a working distance of 5 mm. A high efficiency secondary electron detector was used to image cells. 
2.3 Analysis of Membrane Lipids 
2.3.1 Lipid Extraction To identify what lipids were present in the membranes of the ten strains described here and whether or not there were differences in lipid abundance between methicillin sensitive and methicillin resistant strains, a whole lipid extract was obtained from each strain of S. aureus and individual lipid species identified by ultra-performance liquid chromatography – mass spectrometry (UPLC-MS). The whole lipid extract was obtained using a modified Bligh and Dyer method based on the method found in Hewelt-Belka et 
al. (86). For all ten strains, 10 µL of the bacterial inoculum was added to 190 µL of MHB in separate 1.5 mL Eppendorf tubes. Each tube was then incubated on a benchtop orbital shaker for 20 hours at 35 °C and 100 rpm. After incubation, the cells were centrifuged at 9,000 rcf for 10 minutes to pellet cells. The supernatant was removed and 
the cell pellet resuspended in 90 µL of the solvent mixture (chloroform-methanol 1:2 v/v). Chloroform was obtained from Merck (Bayswater, VIC, Australia) and was UPLC grade. Methanol was obtained from VWR Chemicals (Tingalpa, QLD, Australia) and was UPLC grade. The suspension was then incubated under agitation on a Stuart SA8 vortex mixer (Staffordshire, United Kingdom) for 30 minutes at room temperature and 1000 rpm to disrupt the cell and dissolve the membrane lipids. After agitation, 30 µL of 
chloroform and 25 µL of Milli-Q water was added and the solution centrifuged at 9,000 
rcf for 10 minutes to separate into layers. 50 µL of the lower organic phase containing the membrane lipids was transferred to a glass vial and stored at -20 °C prior to analysis by UPLC-MS. 
2.3.2 Ultra-Performance Liquid Chromatography – Mass Spectrometry for 
Lipidomics Lipids were separated and analysed by UPLC-MS using a method similar to that presented in Damen et al. (87). UPLC was conducted using a Waters Acquity UPLC System (Milford, MA, United States) fitted with a binary solvent manager and mass spectrometric detection was conducted using a Waters Xevo QToF-MS quadrupole time of flight mass spectrometer, fitted with an electrospray source. Separation consisted of two mobile phases. Mobile Phase A (10 mM ammonium acetate (Merck, AR grade, Bayswater, VIC, Australia) with 0.1% formic acid (Honeywell Fluka, MS grade, Seelze, 
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Germany) in Milli-Q water-acetonitrile (Honeywell Burdick & Jackson, LC-MS grade, Muskegon, MI, USA) (ACN) (40:60, v/v)), and Mobile Phase B (10 mM ammonium acetate with 0.1% formic acid in ACN-isopropanol (Honeywell Fluka, LC-MS grade, Seelze, Germany) (IPA) (10:90, v/v)). An Acquity UPLC HSS C18 column (2.1 mm x 150 mm) thermostatted to 45 °C was used. The weak wash consisted of ACN-Milli-Q water- IPA (30:30:40, v/v/v) and the strong wash consisted of IPA and 0.1% formic acid. Elution was achieved at a flow rate of 0.2 mL/minute with each sample run taking 20 minutes. The run conditions are summarised in Table 6. Samples were diluted two-fold in IPA-ACN-Milli-Q water (2:1:1) and 5 µL was injected for each run. UPLC-MS runs were acquired separately in positive mode and negative mode with both modes using the same 20-minute LC method. Data was obtained in technical triplicate. Mass spectrometry was conducted with a capillary voltage of ± 0.6 kV and a sampling cone voltage of ± 30 V for both positive and negative ion mode electrospray ionisations. A desolvation nitrogen gas flow of 700 l/h and a desolvation temperature of 450 °C were used. Data acquisition was conducted over the mass to charge range of 50–1,200. Mass accuracy was obtained using a lockspray solution consisting of 200 ng/mL leucine encephalin in 50% aqueous ACN with 0.1% formic acid. The solution was infused at 5 
µL/min and the lockmass correction updated every 30 seconds. 
Table 6: Run conditions for UPLC-MS for lipidomics.  
Time (Minutes) Mobile Phase A Mobile Phase B 0 60% 40% 2 57% 43% 2.1 50% 50% 11 46% 54% 11.1 30% 70% 17 1% 99% 17.1 60% 40% 20 60% 40%  
2.3.3 Lipid Identification and Analysis A targeted lipid search was conducted using Waters MassLynx v4.1 (Milford, MA, United States) on the total ion chromatograms (TICs) generated by the above UPLC-MS. This was done to first identify any lipid species present in the whole lipid extracts and then to identify their relative abundance and subsequently differences between the lipid species present in the MSSA group and MRSA group. A list of neutral masses of membrane phospholipids and glycolipids from the classes DAG, DGDG, MGDG, PG, CL and Lys-PG was acquired from Hewelt-Belka et al. (88) and the protonated, ammoniated, sodiated and potassiated ion adduct masses calculated by adding the mass of a hydrogen ion, ammonium ion, sodium ion and potassium ion respectively to the neutral masses. The calculated ion adduct masses were used for the targeted lipid search by ion extraction from the TIC. After identification of a lipid species, its relative abundance was calculated from the area under the curve of the extracted ion chromatographic peak and comparisons made between the sensitive and resistant strains. 
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2.4 Analysis of Protein Content 
2.4.1 Protein Extraction A whole protein extract was obtained from each S. aureus strain using a modified Bligh and Dyer method to identify proteins present in each strain and whether or not they differed in abundance between these strains. This method was based on the method found in Hewelt-Belka et al. (86) and similar to the method described above for the lipid extraction. However, rather than analysing the organic layer containing the lipids, the aqueous layer containing the bacterial proteins was the focus. Furthermore, a few modifications were made to the methodology to ensure sufficient protein content was present for all tests. The first change was to the amount of cells used. The same liquid growth set up as described above for the lipid extraction was used but this was repeated five times per strain and the final protein extract from all five repeats pooled together in order to ensure enough of the sample was available for both the determination of the concentration of the whole protein extract and UPLC-MS. After growth each of the five cell suspensions were pipetted into separate weighed 1.5 mL Eppendorf tubes and spun down at 9,000 rcf for 10 minutes to pellet cells. The second adjustment was the volume of the solvent mixture used. For protein extraction, the cell pellet was resuspended in ten times the amount of solvent mixture (chloroform- 
methanol 1:2 v/v) as was used for the lipid extraction (900 µL). The pellet was resuspended by vortexing at 1400 rpm for 15 seconds. The suspension was then incubated under agitation. The third adjustment was the agitation method. This was done on an Eppendorf Thermomixer Comfort (Macquarie Park, NSW, Australia) for 60 minutes at 1000 rpm at 4 °C in the dark in order to disrupt the cells and suspend the protein content. After agitation, the solution was subjected to a quick spin and then 300 
µL of chloroform and 250 µL of Milli-Q water was added and mixed by vortexing at 1400 rpm for 15 seconds. The solution was then centrifuged at 9,000 rcf for 10 minutes to separate into layers. 600 µL of the upper aqueous phase was transferred to a 5 mL Eppendorf tube. This was done five times per strain with the aqueous layers combined together into a single tube. The protein concentration present in the pooled sample was calculated using the Bio-Rad protein assay (Biorad, Gladesville, NSW, Australia) described below. After protein concentration was calculated, the sample was then concentrated overnight using an RVC 2-25 CDplus rotational vacuum concentrator (Martin Christ, Osterode am Harz, Germany) at 1400 rpm and 4 mbar. The solution was evaporated away leaving a protein pellet that was stored at -20 °C prior to digestion. 
2.4.2 Protein Assay A protein assay was conducted to calculate the amount of protein present in the pooled sample described above in order to ensure protein digestion was carried out with the optimal ratio of trypsin to protein. The assay was conducted using the Coomassie Brilliant Blue G-250 dye as part of the Bio-Rad protein assay. The microassay procedure for microplates as described in the Bio-Rad Protein Assay Manual (89) was used. In 
brief, four protein standards (10,20,40 and 80 µg/mL) were made using human serum 
albumin (HSA) (Sigma, Castle Hill, NSW, Australia). 160 µL of each standard, sample and water as a blank were pipetted into separate wells of the microplate. To each standard, 
sample and blank, 40 µL of the undiluted dye reagent was added and mixed using a pipette. The plate was incubated at room temperature for 15 minutes and absorbance 
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measured at 595 nm. The absorbance values for the standards were used to make a standard curve and the curve was used to calculate the concentration of protein present in the samples. 
2.4.3 Digestion of Protein After the protein samples were pelleted and the protein concentration determined by the Bio-Rad assay, the protein pellet was digested by trypsin using the RapidGest SF 
Surfactant Procedure (90). The protein pellet was first suspended in 10 µL of 0.5% RapiGest SF (Waters Milford, MA, United States) and 40 µL of 50 mM ammonium bicarbonate (Chem-Supply, AR grade, Gillman, SA, Australia). The suspension was then vortexed and centrifuged briefly before being incubated on a Ratek model DBH10D heating block (Boronia, VIC, Australia) at 95 °C for 5 minutes. After cooling to room 
temperature, the samples were reduced by adding 50 µL of 10 mM dithiothreitol (Calbiochem, AR grade, San Diego, CA, United States) and incubating on a heating block for 30 minutes at 60 °C. After this the samples were alkylated by adding 100 µL of 30 mM 2-iodoacetamide (Merck, synthesis grade, Bayswater, VIC, Australia) and incubating in the dark at room temperature for 30 minutes. Protein digestion was then carried out 
by adding 100 µL of 10 ng/µL trypsin solution (Promega, MS grade, Alexandria, NSW, Australia) and incubating on a heating block for 16 hours at 37 °C. After overnight 
incubation at 37 °C, the trypsin was inactivated by adding 250 µL of 0.4% trifluoroacetic acid (Scharlau, synthesis grade, Barcelona, Spain). The solution was then centrifuged at 18,730 rcf for 10 minutes in a Velocity 14R refrigerated centrifuge (Dynamica, Clayton, VIC, Australia). The supernatant was transferred to an Eppendorf tube and evaporated in a rotational vacuum concentrator. Twenty microliters of 0.1% formic acid was added to the tube containing the resulting pellet. The tube was then suspended in an ultrasonic cleaner for 10 minutes to dissolve the peptides. This suspension was then transferred to a total recovery chromatographic vial and stored at -20 °C prior to analysis by UPLC-MS. 
2.4.4 Ultra-Performance Liquid Chromatography – Mass Spectrometry for 
Proteomics The digested protein samples were separated and analysed by UPLC-MS. UPLC was conducted using a Waters nanoAcquity UPLC sample manager (Milford, MA, United States) fitted with a binary solvent manager. Mass spectrometric detection was conducted using a Waters Synapt G2-Si (Milford, MA, United States). Separation consisted of two mobile phases. Mobile Phase A (0.1% formic acid in Milli-Q water) and Mobile Phase B (0.1% formic acid in ACN). The trapping column was a Waters nanoEase 
M/Z Symmetry C18 trap column (180 µm x 20 mm) and the analytical column was a 
Waters nanoAcquity UPLC BEH130 C18 column (75 µm x 100 mm). The column was thermostatted to 35 °C. Elution was achieved at a flow rate of 0.3 µL/min with each sample run for 50 minutes. The run conditions are summarised in Table 7. Samples 
were suspended in 0.1% formic acid and 1 µL was injected for each run. Data was obtained in technical triplicate. Mass spectrometry was conducted in positive ion mode with a capillary voltage of 3 kV and a sampling cone voltage of 30 V as well as a source offset of 30 V for electrospray ionisations. The source temperature was set at 80 °C. A desolvation source of nitrogen gas at 600 l/h and a desolvation temperature of 350 °C was used. Lock spray 
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configuration was conducted every 60 seconds with [Glu1]-fibrinopeptide B (Waters Milford, MA, United States) as the reference compound. Data acquisition was conducted over the mass to charge range of 50–2000. The data independent acquisition used an MSE experiment employing both low and high energy collision-induced dissociation of parent ions. Low energy collision was done at 6 V in the trap collision cell and at 4 V in the transfer collision cell. High energy collision used a collision energy ramp from 17 V to 60 V in the transfer collision cell. Scan time was 0.5 seconds and after each scan the system would switch from high to low energy collision. Peptides with a mass of less than 400 were filtered out. 
Table 7: Run conditions for UPLC-MS for proteomics.  
Time (Minutes) Mobile Phase A Mobile Phase B 0 99% 1% 2 90% 10% 40 60% 40% 42 15% 85% 50 15% 85%  
2.4.5 Protein Identification and Analysis Protein identification was carried out using Progenesis QI for Proteomics (Waters, Milford, MA, United States). Peptides were identified in Progenesis using the UniProt S. 
aureus database and with the following conditions. The allowed maximum missed cleavages was 1, the allowed false discovery rate was set to 4% and the maximum protein size was set to 250 kDa. In addition, the peptide modifications were set to variable and included carbamidomethyl C, deamidation N, deamidation Q, oxidation M and propionamide C. The ion matching requirements were fragments/peptide of 1 or more, fragments/protein of 3 or more and peptides/protein of 1 or more. Two experimental conditions were set up. The first compared the five methicillin sensitive strains as a group against the five methicillin resistant strains as a group. The second condition compared all ten strains against each other. In both experimental conditions, proteins identified with a p-value ≤ 0.05 and a fold change ≥ 2 were considered significant. 
2.5 Analysis of Cell Wall Thickness 
2.5.1 Resin Embedding In order to identify any differences in cell wall thickness between methicillin sensitive and methicillin resistant strains of S. aureus all ten strains were cultured, fixed, dehydrated and embedded in resin. Initially, separate 1.5 mL Eppendorf tubes with 10 
µL of the bacterial inoculum in 190 µL of MHB were made up and incubated on a benchtop orbital shaker for 20 hours at 35 °C and 100 rpm. However, after a failure to identify cells in the subsequent resin blocks, later experiments increased the amount of cells present by instead taking a heavy inoculum from overnight plate grown cultures 
using an inoculating loop and suspending directly into 200 µL of MHB. This cell suspension was then fixed, dehydrated and embedded in resin. This was done by first centrifuging the cell solution at 9,000 rcf for 10 minutes to pellet cells and removing the 
supernatant. The cell pellet was then washed three times in 200 µL 0.1 M Na-phosphate 
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buffer (pH 7.4) before being suspended in 200 µL of the primary fixative, 2.5% glutaraldehyde in 0.1 M Na-phosphate buffer for overnight incubation at 4 °C. After overnight incubation at 4 °C, cells were centrifuged at 9,000 rcf for 10 minutes to remove the supernatant and washed three times in 0.1 M Na-phosphate buffer. Cells 
were then suspended in 200 µL of the secondary fixative, 1% osmium tetroxide (ProSci Tech Kirwan, QLD, Australia), and incubated at room temperature for 2 hours. After incubation, the osmium tetroxide was removed by centrifuging at 9,000 rcf for 10 minutes and the cells were washed three times with Milli-Q water following the same procedure as was used for 0.1 M Na-phosphate buffer. Samples were then dehydrated in an ethanol series by suspending in ethanol and incubating at room temperature for 10 minutes as was done for SEM samples. However, the ethanol concentrations used for scanning transmission electron microscopy (STEM) sample preparation differed from those used in SEM sample preparation. The ethanol concentrations used were 30%, 50%, 70%, 95%, and 100% ethanol. The 100% ethanol step was repeated a total of three times with a ten-minute incubation each time rather than a single one-hour incubation as was done for SEM. After ethanol dehydration, cells were then dehydrated with acetone (Merck, Bayswater, VIC, Australia) as it would evaporate away in the drying step whereas ethanol would remain. This helped to prevent the resulting resin block from being brittle and hard to section. Cells were suspended in 100% acetone for 10 minutes before being removed by centrifugation as was done for ethanol. The 100% acetone step was conducted twice. After dehydration in acetone the cells were spun down at 9,000 rcf for 10 minutes and a loopful taken from the cell pellet using an inoculating loop. The loopful of cells was then streaked directly into resin in a vertical plastic micromould. The resin makeup is summarised in Table 8. All resin ingredients were obtained from ProSci Tech (Kirwan, QLD, Australia). The moulds filled with resin and cells were then placed in an oven overnight at 60 °C to polymerise and harden. Hardened resin blocks were stored at room temperature prior to being sectioned on an ultramicrotome. 
Table 8: Resin makeup for scanning transmission electron microscopy samples.  
Ingredient Amount (g) ERL 4221 10 Der 732 6 Nonenyl succinic anhydride (NSA) 26 Dimethylaminoethanol (DMAE) 0.4  
2.5.2 Resin Block Sectioning Resin blocks were sectioned using a Leica EM UC7 ultramicrotome (Leica Microsystems, Macquarie Park, NSW, Australia) equipped with a glass blade. Samples were sectioned into ultrathin slices, 90 nm thick, before being mounted on a 200 mesh copper grid for examination by STEM. 
2.5.3 Scanning Transmission Electron Microscopy Cells were examined by STEM using a Zeiss Merlin FE-SEM. This was done at 30 kV and 
at a working distance of 2.7 mm. An aperture size of 30 µm was used initially, however, after some difficulty with the electron beam puncturing the resin slice, subsequent 
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imaging was done with an aperture size of 20 µm. A STEM detector was used to image cells. The cell wall of 20 cells were imaged per strain and the cell wall thickness was measured at four points using ImageJ. 
2.6 Determination of Whole-Cell Surface Charge A cytochrome c binding assay was used to determine the whole-cell surface charge of all ten strains of S. aureus and identify if there was any significant difference between the whole-cell surface charge of the methicillin sensitive and methicillin resistant strains. Cytochrome c is highly positively charged and therefore binding is dependent on the net negative surface charge of S. aureus cells. The higher the negative charge, the more cytochrome c will bind to cells. The procedure used was based on Matsuo et al. (91) and 
Meehl et al. (92). Cells were grown overnight in MHB to a final concentration of ≈109 
CFU/mL. This was achieved by adding 50 µL of the bacterial inoculum to 450 µL of MHB and incubating at 35 °C for 20 hours on a shaking incubator at 100 rpm. After incubation, the cells were centrifuged at 9,000 rcf for 10 minutes and the supernatant 
removed. The pellet was then resuspended in 250 µL of 20 mM morpholinepropanesulfonic acid (MOPS) (Sigma, Castle Hill, NSW, Australia), pH 7, and then centrifuged at 9,000 rcf for 10 minutes. This was done twice with fresh MOPS each time. Cells were then suspended in 0.25 mg/mL cytochrome c (Sigma Castle Hill, NSW, Australia), in MOPS and incubated in the dark at room temperature for 10 minutes. After incubation the cell solution was centrifuged at 9,000 rcf for 10 minutes and the supernatant collected. The supernatant was again centrifuged at 9,000 rcf for 10 minutes to ensure no cells remained to interfere with absorbance readings. The amount of cytochrome c in the supernatant was determined at OD530 using a standard curve with 10 cytochrome c standards between 0.025 mg/mL and 0.25 mg/mL as a reference. To ensure the standard curve was reliable a 0.15 mg/mL and 0.25 mg/mL reference sample was included with each experiment. Three independent experiments were run for all ten strains to determine the mean percentage of cytochrome c bound to cells. 
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3. Results 
3.1 In vitro Antimicrobial Testing 
3.1.1 Permethrin Exposure To identify any effect of permethrin on the growth of S. aureus cells, all ten strains were grown in the presence of 1.25%, 2.5%, 5% and 10% permethrin. The effect of exposure to permethrin at these concentrations is presented in Figure 14 as the average percent inhibition of three separate runs. 1.25% permethrin showed inhibition ranging from 0% to 34%, 2.5% permethrin showed inhibition ranging from 0% to 23%, 5% permethrin showed inhibition ranging from 0% to 32% and 10% permethrin showed inhibition ranging from 0% to 32%.  
Figure 14: Percent inhibition of S. aureus cells grown in the presence of 1.25%, 2.5%, 5% and 10% permethrin with standard deviation of the mean error bars. 
3.1.2 Formaldehyde Exposure To identify any effect of formaldehyde on the growth of S. aureus cells, all ten strains were grown in the presence of 0.07%, 0.15%, 0.3% and 0.6% formaldehyde. The effect of exposure to formaldehyde at these concentrations is presented in Figure 15 as average percent inhibition of three separate runs. All concentrations of formaldehyde exhibited 100% inhibition against all tested strains.
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Figure 15: Percent inhibition of S. aureus cells grown in the presence of 0.07%, 0.15%, 0.3% and 0.6% formaldehyde with standard deviation of the mean error bars. 
3.1.3 Permethrin and Formaldehyde Combination Exposure To determine if permethrin and formaldehyde could work together against S. aureus cells, combination exposure experiments were conducted. In these experiments, all ten strains of S. aureus were grown in the presence of 0.3% formaldehyde, 5% permethrin, both 0.3% formaldehyde and 5% permethrin and MHB as a control. The effect of exposure to each of these conditions is presented in Figure 16 as average percent inhibition of three separate runs. Five percent permethrin alone showed inhibition ranging from 0% to 41%. 0.3% formaldehyde both alone and in combination with 5% permethrin showed 100% inhibition of bacterial growth.  
 
Figure 16: Percent inhibition of S. aureus cells grown in the presence of 0.3% formaldehyde, 5% permethrin and a combination of 0.3% formaldehyde and 5% permethrin with standard deviation of the mean errors bars.
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One unexpected observation is that the percent inhibition by 5% permethrin in Figure 14 and Figure 16 are not similar as would be expected. In addition, permethrin inhibition was not concentration dependent. This may be due to the use of different batches of permethrin when making up the permethrin stock. Over the course of the experiments, several batches of permethrin were ordered from Sigma. Initially this came in the form of a powder but later batches were in a semi solid form. This difference in permethrin batches may have played a role in the discrepancies seen between the experiments. Alternatively, the differences may have been due to difficulty in completely dissolving permethrin into MHB as permethrin does not readily dissolve in water. To address this, an ultrasonic cleaner and heating to 37 °C was used to assist in the dissolving process. However even with this the permethrin may not have completely dissolved or may not have dissolved in identical amounts between experiments. Dimethyl sulfoxide (DMSO) or methanol may have been more suitable to dissolve permethrin in but these would have interfered with the inhibition testing as they are capable of inhibiting bacterial growth on their own and so were unable to be used in the experiments. Regardless of these issues the results still indicate a lack of significant antibacterial effect in permethrin. 
3.1.4 Time-Kill Assay To determine the time that 0.3% formaldehyde and 5% permethrin alone and in combination exert their antibacterial effect against S. aureus, a time-kill assay was conducted. The results for MSSA 1 and MRSA 1 are shown as time-kill curves in Figure 17. For both MSSA 1 and MRSA 1 both the 5% permethrin and the control groups grew at a similar rate with no significant difference in the bacterial concentrations. The 0.3% formaldehyde and 0.3% formaldehyde and 5% permethrin combination groups exhibited zero growth at all time points.
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Figure 17: Time-kill curves of S. aureus grown in the presence of 5% permethrin, 0.3% formaldehyde and a combination of 0.3% formaldehyde and 5% permethrin with standard deviation of the mean error bars. A) MSSA 1. B) MRSA 1. Time-kill assays were conducted on the remaining eight strains however, due to the results presented in Figure 17, only the positive control and 0.3% formaldehyde and 5% permethrin combination were investigated. These are shown as time-kill curves in Figure 18 and Figure 19. All eight S. aureus strains showed similar growth in the control and all exhibited complete inhibition in the combination treatment at all time points. 
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Figure 18: Time-kill curves of methicillin sensitive S. aureus grown in the presence of 0.3% formaldehyde and 5% permethrin with standard deviation of the mean error bars. A) MSSA 2. B) MSSA 4. C) MSSA 6. D) MSSA 8.     
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Figure 19: Time-kill curves of methicillin resistant S. aureus grown in the presence of 0.3% formaldehyde and 5% permethrin with standard deviation of the mean error bars. A) MRSA 2. B) MRSA 8. C) MRSA 9. D) MRSA 13. 
3.1.5 Scanning Electron Microscopy Imaging of Permethrin Treated Cells Representative SEM micrographs of each strain of S. aureus grown in either MHB or 5% permethrin are shown in Figure 20 and Figure 21. The former shows the methicillin sensitive strains and the latter shows the methicillin resistant strains. No difference in the morphology nor obvious signs of cell damage can be seen in the SEM micrographs of the permethrin treated cells. 
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Figure 20: Scanning electron micrographs of methicillin sensitive S. aureus cells grown in Mueller Hinton Broth (MHB) or 5% permethrin. Cells imaged using a Zeiss Merlin FE- SEM at 1 kV with a working distance of 5 mm. A) MSSA 1 grown in MHB. B) MSSA 1 grown in permethrin. C) MSSA 2 grown in MHB. D) MSSA 2 grown in permethrin. E) MSSA 4 grown in MHB. F) MSSA 4 grown in permethrin. G) MSSA 6 grown in MHB. H) MSSA 6 grown in permethrin. I) MSSA 8 grown in MHB. J) MSSA 8 grown in permethrin. 
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Figure 21: Scanning electron micrographs of methicillin resistant S. aureus cells grown in Mueller Hinton Broth (MHB) or 5% permethrin. Cells imaged using a Zeiss Merlin FE- SEM at 1 kV with a working distance of 5 mm. A) MRSA 1 grown in MHB. B) MRSA 1 grown in permethrin. C) MRSA 2 grown in MHB. D) MRSA 2 grown in permethrin. E) MRSA 8 grown in MHB. F) MRSA 8 grown in permethrin. G) MRSA 9 grown in MHB. H) MRSA 9 grown in permethrin. I) MRSA 13 grown in MHB. J) MRSA 13 grown in permethrin. 
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3.2 Studies on Methicillin Sensitive and Methicillin Resistant Strains of S. aureus 
3.2.1 Cell Membrane Lipids Lipids successfully identified by a manual targeted lipid search in the whole lipid extracts of the S. aureus strains are shown in Table 9. The ion adducts identified, theoretical mass and observed mass are also presented. The identified species included members of the classes DAG, DGDG, Lys-PG and PG. 
Table 9: Lipid species identified in all ten S. aureus strains. Identified ion adduct, theoretical mass and observed mass also presented.  
Lipid Species Ion Adduct Theoretical Mass Observed Mass 
DAG (30:0) [M + K]+ 579.439 579.453 
DAG (32:0) [M + K]+ 607.470 607.482 
DAG (34:0) [M + NH4]+ 614.572 614.574 
DAG (36:0) [M + NH4]+ 642.604 642.59 
DGDG (30:0) [M + NH4]+ 882.615 882.603 
DGDG (31:0) [M + Na]+ 901.586 901.57 
DGDG (32:0) [M + NH4]+ 910.647 910.609 
DGDG (33:0) [M + NH4]+ 924.662 924.632 
DGDG (34:0) [M + NH4]+ 938.678 938.627 
DGDG (35:0) [M + NH4]+ 952.694 952.648 
Lys-PG (18:0) [M + Na]+ 677.375 677.359 
Lys-PG (25:0) [M + H]+ 753.503 753.505 
Lys-PG (27:0) [M + H]+ 781.534 781.540 
Lys-PG (29:0) [M + H]+ 809.566 809.56 
Lys-PG (32:0) [M + H]+ 851.613 851.611 
Lys-PG (33:0) [M + NH4]+ 882.655 882.603 
Lys-PG (35:0) [M + NH4]+ 910.686 910.609 
Lys-PG (36:0) [M + Na]+ 929.657 929.627 
Lys-PG (37:0) [M + Na]+ 943.673 943.620 
Lys-PG (38:0) [M + Na]+ 957.688 957.658 
PG (32:0) [M + NH4]+ 740.544 740.524 
PG (35:0) [M + NH4]+ 782.591 782.567  The relative abundances of the identified lipid species as calculated by the area under the curve of the extracted ion chromatographic peak are presented in Table 10 as the average relative abundance in the MSSA group and the average relative abundance in the MRSA group. In addition to the average relative abundances, the difference between the abundance in the MSSA group and the MRSA group are also shown (as relative abundance in MSSA group minus relative abundance in MRSA group). Finally, the calculated p-values from a Welch Two Sample t-test at a significance of p ≤ 0.05 looking for a statistically significant difference between the average abundances of each lipid species in the MSSA group and MRSA group is also presented. 
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Table 10: Lipid species and average relative abundances. Average relative abundance present in MSSA group and MRSA group along with difference in abundance between the two groups is shown. The calculated p-value from a t-test looking for significant difference between the resistant and sensitive strains is also presented.  
Lipid Species Average 
Relative 
Abundance in 
MSSA Group 
Average 
Relative 
Abundance in 
MRSA Group 
Difference 
(MSSA-MRSA) 
p-Value 
DAG (30:0) 4235 4056 179 0.7633 
DAG (32:0) 2801 2745 56 0.8721 
DAG (34:0) 1870 2073 -203 0.613 
DAG (36:0) 1836 1670 166 0.6055 
DGDG (30:0) 1073 862 211 0.0997 
DGDG (31:0) 1155 1395 -240 0.3094 
DGDG (32:0) 3219 2856 363 0.3868 
DGDG (33:0) 1280 1076 204 0.2757 
DGDG (34:0) 2220 1838 382 0.003428 
DGDG (35:0) 1340 970 370 0.1043 
Lys-PG (18:0) 870 879 -9 0.9863 
Lys-PG (25:0) 743 741 2 0.9939 
Lys-PG (27:0) 1243 1264 -21 0.8847 
Lys-PG (29:0) 160 178 -18 0.5489 
Lys-PG (32:0) 1914 1122 792 0.000003282 
Lys-PG (33:0) 1073 1176 -103 0.5925 
Lys-PG (35:0) 3520 3745 -225 0.3636 
Lys-PG (36:0) 740 608 132 0.0912 
Lys-PG (37:0) 1160 983 177 0.1118 
Lys-PG (38:0) 810 634 176 0.0041 
PG (32:0) 2278 2149 129 0.5967 
PG (35:0) 367 370 -3 0.9398  The three lipid species with significant differences between the MSSA group and MRSA group are shown in Figure 22 as extracted ion chromatograms of representative strains. 
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Figure 22: Representative extracted ion chromatograms for lipid species with significant differences between MSSA group and MRSA group. A) DGDG (34:0). B) Lys- PG (32:0). C) Lys-PG (38:0). 
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3.2.2 Protein Content All ten strains were subject to protein extraction and this protein extract was quantified using the Bio-Rad protein assay to ensure optimal use of trypsin. Each protein extract had a final volume of 2 mL before digestion by trypsin. The concentration of protein in each extract is summarised in Table 11. 
Table 11: Protein concentration in each S. aureus strain’s whole protein extract as determined by the Bio-Rad protein assay.  
Strain Protein Concentration (µg/mL) MSSA 1 70 ± 5 MSSA 2 56 ± 4 MSSA 4 80 ± 2 MSSA 6 62 ± 4 MSSA 8 61 ± 2 MRSA 1 70.5 ± 0.9 MRSA 2 50 ± 1 MRSA 8 75 ± 4 MRSA 9 61.6 ± 0.1 MRSA 13 62 ± 1  After identification of proteins by UPLC-MS, their normalised abundances were compared between the MSSA group and the MRSA group. Proteins with a fold change of at least 2 between these groups are shown in Table 12. 
Table 12: Proteins identified with a p-value ≤ 0.05 and a fold change ≥ 2 between the MSSA group and the MRSA group.  
UniProt 
Accession 
Number 
Protein Identification p-Value Fold 
Change 
Group with 
Highest 
Mean A5ISF8 Polyribonucleotide nucleotidyltransferase 0.0000619 2.155 MSSA A5ISE7 Proline-tRNA ligase 0.001449695 5.254 MSSA A5ISF3 Translation initiation factor IF-2 0.002003652 2.389 MRSA Q6GEA1 Formimidoylglutamase 0.004315119 2.137 MSSA Q6GIB7 Coenzyme A disulphide reductase 0.008195579 2.186 MRSA A5IUX8 6-phospho-beta- galactosidase 0.018369997 2.313 MSSA A5IV27 50S ribosomal protein L16 0.026063696 2.192 MRSA A5IT64 Probable glycine dehydrogenase (decarboxylating) subunit 1 
0.027961214 2.333 MRSA 
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After identifying proteins present at significant differences between the MSSA group and the MRSA group, the identified proteins were then compared between strains. Of particular focus were the proteins presented in Table 12 and virulence factors. The proteins with fold changes greater than 2 between strains are shown in Table 13. 
Table 13: Proteins identified with a p-value ≤ 0.05 and a fold change ≥ 2 between strains and their function.  
UniProt 
Accession 
Number 
Protein Identification Function* p-Value 
A5ISF8 Polyribonucleotide nucleotidyltransferase Involved in the degradation of mRNA. 0.0000619 A5IQ93 50S ribosomal protein L10 Forms part of the ribosomal stalk and therefore plays a central role in the interaction of the ribosome with GTP- bound translation factors. 
0.000733 
A5ISE7 Proline-tRNA ligase Catalyses the attachment of proline to tRNA. 0.00145 A5ISF3 Translation initiation factor IF-2 One of the essential components for the initiation of protein synthesis. 
0.00200 
A7WYS8 Lysine-tRNA ligase Catalyses the attachment of lysine to tRNA. 0.00212 A5IV27 50S ribosomal protein L16 Binds 23S rRNA. Also seen to make contact with tRNA at the A and P site. 
0.0261 
Q6GEA1 Formimidoylglutamase Catalyses the conversion of N-formimidoyl-L- glutamate to L-glutamate and formamide. 
0.00432 
P0A039 Glutamine synthetase Functions as an enzyme, a transcription coregulator and chaperone in ammonium assimilation and in the regulation of genes involved in nitrogen metabolism. 
0.00750 
Q6GIB7 Coenzyme A disulphide reductase Catalyses the NADPH- dependent reduction of coenzyme A disulphide. 0.00820 A5IUX8 6-phospho-beta- galactosidase Involved in the step that synthesises D-galactose 6- phosphate and beta-D- glucose from lactose 6- 
0.0184 
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  phosphate as part of the lactose degradation pathway.  A5IT64 Probable glycine dehydrogenase (decarboxylating) subunit 1 
Plays a role in the glycine cleavage system. 0.0280 
Q5HHC7 NAD-specific glutamate dehydrogenase Catalyses the reversible conversion of glutamate to α-ketoglutarate and ammonia while reducing NAD(P)+ to NAD(P)H. 
0.0490 
Q2FYK3 Conserved virulence factor C Required for haemolysin production. 0.00000000238 P0A0J1 Superoxide dismutase [Mn/Fe] 1 Destroys superoxide anion radicals which are toxic to biological systems. 0.0000686 A0A0H2XI99 ESAT-6 secretion system extracellular protein A Virulence factor that is important for the establishment of infection in the host. 
0.0000846 
P81177 Zinc metalloproteinase aureolysin Plays an essential role in immune evasion by helping bacteria to resist killing by neutrophils. 
0.000630 
Q14U76 Bone sialoprotein- binding protein Specifically interacts with bone sialoprotein to contribute to staphylococcal osteomyelitis and arthritis. 
0.00114 
Q2G2J2 Staphylococcal secretory antigen ssaA2 An immunogenic protein whose function is not known. 0.00427 *Protein function obtained from UniProt The normalised abundances of the proteins presented in Table 13 are shown in Figure 23. From these figures it is possible to visualise the differences in specific protein abundance between strains. 
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Figure 23: Normalised abundance of proteins in each S. aureus strain. Protein defined by UniProt accession number. A) A5ISF8. B) A5IQ93. C) A5ISE7. D) A5ISF3. E) A7WYS8. F) A5IV27. G) Q6GEA1. H) P0A039. I) Q6GIB7. J) A5IUX8. K) A5IT64. L) Q5HHC7. M) Q2FYK3. N) P0A0J1. O) A0A0H2XI99. P) P81177. Q) Q14U76. R) Q2G2J2. 
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3.2.3 Cell Wall Thickness Representative images of the sectioned S. aureus cells examined by STEM and used to determine cell wall thickness are shown in Figure 24 and an example of how the bacterial cell walls were measured is shown in Figure 25.  
Figure 24: Scanning transmission electron micrographs of S. aureus cells embedded in resin and sectioned on an ultramicrotome. Cells imaged using a Zeiss Merlin FE-SEM at 
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30 kV and a working distance of 2.7 mm. A) MSSA 1. B) MSSA 2. C) MSSA 4. D) MSSA 6. E) MSSA 8. F) MRSA 1. G) MRSA 2. H) MRSA 8. I) MRSA 9. J) MRSA 13.  
Figure 25: Example of procedure used for measurement of bacterial cell walls. MRSA 1 cell with four points on the cell wall indicated. The average cell wall thickness for each strain as calculated from 20 cells is presented in Figure 26. To identify any significant difference between the cell wall thickness of any of the 10 strains, a one-way ANOVA was conducted in R at a significance of p ≤ 0.05. The p- value was calculated to be 2.24x10-10 and therefore the cell wall thickness of the different S. aureus strains differ significantly from each other. As a result of this observed significance, a pairwise comparison of means was also conducted in R in order to determine which strains differed from each other. The strain pairs with significant differences and their respective p-values are shown in Table 14.               
Figure 26: Average cell wall thickness of ten strains of S. aureus cells with standard deviation of the mean error bars. 
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Table 14: S. aureus strain pairs with significant difference in cell wall thickness and respective p-values.  
Strain Pair p-Value MSSA 2 - MRSA 2 <0.01 MSSA 2 - MRSA 9 <0.01 MSSA 6 - MSSA 1 <0.01 MSSA 6 - MSSA 2 <0.01 MSSA 6 - MSSA 4 <0.01 MSSA 6 - MRSA 1 <0.01 MSSA 6 - MRSA 8 <0.01 MSSA 6 - MRSA 13 <0.01 MSSA 8 - MSSA 2 <0.01 MRSA 9 - MRSA 8 0.0480  The average cell wall thickness of the resistant strains and the sensitive strains as calculated from the measurements in Figure 26 is presented in Figure 27. A Welch Two Sample t-test was conducted in R at a significance of p ≤ 0.05 looking for a statistically significant difference between the averages of the resistant strains and the sensitive strains. The calculated p-value for this test was 0.9502.               
Figure 27: Average cell wall thickness of MSSA group and MRSA group of S. aureus with standard deviation of the mean error bars. 
3.2.4 Whole-Cell Surface Charge The average percent bound cytochrome c as determined from three repeat experiments for each of the ten strains used in the experiment is shown in Figure 28. To determine if there was a significant difference between the percent bound cytochrome c in each strain a one-way ANOVA was conducted in R at a significance of p ≤ 0.05. The p-value was determined to be 0.875 and therefore it was concluded that there is no significant difference between the percent bound cytochrome c of any of the 10 strains meaning there was no need to conduct a pairwise comparison of means. 
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Figure 28: Percent binding of cytochrome c to ten strains of S. aureus cells with standard deviation of the mean error bars. The average percent bound cytochrome c was determined for the MSSA group and the MRSA group and is shown in Figure 29. A Welch Two Sample t-test was conducted in R 
at a significance of p ≤ 0.05 looking for a statistically significant difference between the averages of the percent bound cytochrome c in the MSSA group and the MRSA group. The calculated p-value for this test was 0.3437.               
Figure 29: Percent binding of cytochrome c to S. aureus cells in the MSSA group and the MRSA group with standard deviation of the mean error bars. 
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4. Discussion 
4.1 Antibacterial Activity of Permethrin Cream In Whitehall et al. (4) the use of a 5% permethrin cream in patients with scabies and impetigo was associated with a decrease in infection with antibiotic resistant S. aureus. Permethrin is a common insecticide used in the treatment of scabies infections (3) and while permethrin’s insecticidal effects are well characterised there is no report of it containing direct antibacterial activity. There are however reports of exposure to permethrin affecting gut microbiota. For example, exposure to permethrin reduced the abundance of Bacteroides, Prevotella, and Porphyromonas while increasing the abundance of Enterobacteriaceae and Lactobacillus in rat gut microbiota (93). Furthermore, in permethrin exposed mosquitoes, the insecticide degrading bacterial species Pantoea agglomerans along with Pseudomonas fragi and other bacterial species were found to be in higher abundances than in non-exposed mosquitoes (94). These reports show that permethrin is capable of altering bacterial populations in some way. 
4.1.1 Effect of Permethrin To determine whether or not permethrin is capable of directly affecting the growth of bacteria, ten strains of S. aureus (five methicillin sensitive and five methicillin resistant) were grown in the presence of four concentrations of permethrin and percent inhibition determined from viable counts. In all four of these conditions, the percent inhibition after 20 hours was not indicative of significant antibacterial activity. None of the conditions exceeded 40% inhibition with a majority being below that. Furthermore, in many cases, the CFU/mL in the permethrin treated samples were equal to or higher 
than that of the control. As this was well below the ≥ 99.9% inhibition required to be termed bactericidal, permethrin clearly has poor antibacterial properties. 
4.1.2 Effect of Formaldehyde As permethrin is a poor antibacterial, some other component of the permethrin cream used in Whitehall et al. (4) must have been responsible for the observed antibacterial activity. This cream contained 0.3% formaldehyde as a preservative. Formaldehyde is known to have strong antibacterial properties and therefore the preservative may have been responsible for the observed antibacterial activity. To test this the ten strains of S. 
aureus were grown in the presence of four concentrations of formaldehyde with viable counts determined. The percent inhibition was observed to be much more significant than for permethrin with 100% inhibition observed at all formaldehyde concentrations in all ten strains. It is therefore likely that formaldehyde was responsible for the observed antibacterial activity in Whitehall et al. (4). 
4.1.3 Effect of Combination of Permethrin and Formaldehyde To confirm that the presence of permethrin does not interfere with formaldehyde’s antibacterial action, combination inhibition experiments were conducted. The same ten strains of S. aureus were grown in the presence of 5% permethrin, 0.3% formaldehyde and a combination of 0.3% formaldehyde and 5% permethrin with percent inhibition again determined by viable counts. The percent inhibition of the 5% permethrin alone was as expected based on the prior experiments with no inhibition above 41% and a majority lower with some cases of the CFU/mL of permethrin treated cells being equal 
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to or higher than the control. Both 0.3% formaldehyde alone and in combination with 5% permethrin was capable of inhibiting 100% of growth in all ten strains. This suggests that permethrin does not interfere with the antibacterial activity of formaldehyde. While the combination assay was able to show that permethrin does not act antagonistically with formaldehyde, due to formaldehyde inhibiting 100% of growth in the 20-hour period, there was no way to determine if permethrin acted synergistically or neutrally. To further explore this combinational activity and determine how permethrin interacts with the action of formaldehyde, a time-kill assay was conducted with the same concentrations of permethrin and formaldehyde as used above. This also allowed for further insight into how permethrin alone affected the growth of S. aureus. Two strains of S. aureus (MSSA 1 and MRSA 1) were grown in the presence of 0.3% formaldehyde, 5% permethrin, both 0.3% formaldehyde and 5% permethrin and MHB alone as a positive control. The rate of growth of both strains in 5% permethrin was very similar to that of the control. This further illustrates the poor antibacterial activity of permethrin. Furthermore, 0.3% formaldehyde both alone and in combination with permethrin was highly bactericidal with a CFU/mL of 0 even at the zero-hour time point. This implies that on contact with formaldehyde, all bacterial cells were killed with no latency in this activity. Permethrin did not slow this action down. After observing this effect for a methicillin sensitive and a methicillin resistant strain, the time-kill assay was conducted on the remaining eight strains with only the positive control and the 0.3% formaldehyde and 5% permethrin combination treatment to confirm that all ten strains exhibited the same rapid killing in the presence of formaldehyde and permethrin. The same complete inhibition observed in MSSA 1 and MRSA 1 at zero- hours was observed in the remaining eight strains exposed to the combination of formaldehyde and permethrin with no resurgence in growth at any later time points. While the above results indicate that permethrin alone is a poor inhibitor of bacterial growth, it may be possible that exposure to permethrin alters the cell’s morphology or size. This could be either due to the action of permethrin itself or through the cell’s attempt to survive the presence of permethrin. In order to identify if exposure to permethrin had any effect on the morphology of S. aureus cells, all ten strains were grown in the presence of 5% permethrin and examined under SEM. It was observed that both the treated and untreated samples exhibited similar morphology. All samples showed healthy cocci cells as is expected of S. aureus with no indication of forced cell death, cell shrinkage, lysis or alterations to cell shape or size in the permethrin treated samples. Furthermore, in some images it appeared as though the S. aureus cells were growing healthily even while surrounded by and embedded into permethrin. These results imply that S. aureus is capable of growing well when exposed to 5% permethrin. Formaldehyde is known to possess strong antibacterial activity with an MIC against S. 
aureus of 156 mg/L (0.02%) (46) and is commonly used as a preservative in cosmetics and medicinal creams. Therefore, it is most likely that the antibacterial activity observed in Whitehall et al. (4) was a result of the formaldehyde preservative present in the permethrin cream rather than the activity of permethrin itself against S. aureus. This is supported by the low to negative inhibition observed after exposure to permethrin 
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and complete inhibition when exposed to any tested concentration of formaldehyde in the solo treatment, combinational treatment and time-kill assays. The observed healthy cells in the SEM micrographs of permethrin treated S. aureus cells further support the idea that permethrin has poor antibacterial activity against S. aureus. While this means that permethrin is not capable of significantly inhibiting bacterial growth and therefore unable to be used as a novel treatment against antibiotic resistant bacterial infections, these results do bring to attention the potential for a formaldehyde cream to serve as a potential treatment for infections with antibiotic resistant bacteria. 
4.1.4 Formaldehyde as an Alternative to Antibiotics for Treating Skin Infections Formaldehyde represents a potential alternative to conventional antibiotics for treating bacterial infections in humans. It could be applied as a topical cream and would be cheaper and very useful in cases where antibiotics have failed, such as refractory impetigo or for strains resistant to multiple antibiotics. The risks associated with formaldehyde use in humans would need to be considered and investigated further than available in the literature before it can be recommended for treatment of bacterial infections. 
4.1.4.1 Risks Associated with Formaldehyde In order for formaldehyde to be used as an alternative treatment, the risks associated with its use would need to be considered. Formaldehyde gas, when inhaled, can cause a wide range of harmful effects ranging from sensory irritation to development of nasopharyngeal cancer (95,96). Furthermore, formaldehyde is responsible for causing allergic contact dermatitis in formaldehyde-allergic individuals (97). 
4.1.4.2 Dermal Application of Formaldehyde Despite the wealth of knowledge on the harmful effects of airborne formaldehyde, significantly less is known about the effects of dermal application of formaldehyde in non-allergic humans. The majority of the limited studies conducted on the effect of dermally applied formaldehyde were written in the late 80s. For example, an experiment was conducted by Iversen (98) in which a formaldehyde cream was applied to mice to identify any cancer inducing properties. It was found to be unable to induce cancer alone but was able to shorten latency time in induced carcinogenesis. Iversen later repeated the experiment on SENCAR mice which are more sensitive to chemical tumorigenesis and found similar results as in his initial study (99). There is however, a more recent study regarding dermal application of formaldehyde conducted by Saito et al. (100). In this study, the irritant effects of dermally applied formaldehyde were investigated. This was done by applying 2%, 5% and 10% solutions of formaldehyde onto mice ears and measuring ear swelling. It was observed that swelling and expression of IL-4 increased with formaldehyde concentration. While this study does show irritant activity it does so at relatively high concentrations and is limited in that the minimal concentration required to exert irritant activity was not identified. In addition to the limited studies on the effect of dermally applied formaldehyde in healthy individuals, there is also a lack of information regarding formaldehyde absorption through human skin. No in vivo human studies on the rate of absorption though human skin were found. There is however some information on the rate of 
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formaldehyde absorption using animals and excised human skin as test subjects that can be used to make assumptions on the rate of formaldehyde absorption through human skin. One such study includes an animal study by Bartnik Gloxhuber & Zimmerman (101) that looked at formaldehyde’s rate of absorption through the skin of rats. This was done by applying a cream containing radioactively tagged formaldehyde (0.1%) to rats and measuring absorption after 48 hours. It was found that no more than 5% of the applied formaldehyde was absorbed through the skin of rats. Another animal study (102) tested formaldehyde absorption on rats, guinea-pigs and monkeys. This study found no accumulation of formaldehyde in any tissue. It also concluded that the skin of monkeys was less permeable to formaldehyde than the skin of rodents and a majority of formaldehyde was lost to evaporation. The lack of formaldehyde buildup in organs is supported by almost every body tissue having the ability to break it down into the nontoxic formate (103). A study using excised human skin (104) found the rate of absorption varied based on concentration of formaldehyde and the solvent formaldehyde was dissolved in. A 37% formalin solution was absorbed at a rate of 319 
µg/cm2/h and a 10% solution of formaldehyde in phosphate buffer was absorbed at a 
rate of 16.7 µg/cm2/h. These reports though old and limited do indicate poor absorption of formaldehyde through healthy skin. 
4.1.4.3 Absence of Formaldehyde Resistance in Bacteria In addition to its high antibacterial activity even at low concentrations, formaldehyde has the added benefit of being difficult for bacteria to develop resistance to. While certain species of bacteria such as Amycolatopsis methanolica and Mycobacterium gastri exhibit tolerance to formaldehyde due to the presence of formaldehyde dismutase that is able to break down formaldehyde, both A. methanolica and M. gastri are still susceptible to formaldehyde at concentrations above 0.8 mM (48). Furthermore, it is accepted that formaldehyde resistance is most often found in Gram-negative bacteria (49) with no cases of formaldehyde resistance in S. aureus reported in the literature. 
4.1.4.4 Formaldehyde for Treating Skin Infections When taken together, the available information on formaldehyde and its harmful effects when applied dermally, though old, does indicate that formaldehyde may be relatively safe for use in humans when applied dermally at low concentrations (provided the individual in question is not allergic) as it is poorly absorbed and when absorbed is rapidly converted to non-toxic formate. When this is combined with the potent antibacterial activity of formaldehyde and the difficulty bacteria have in developing adequate resistance to it, a formaldehyde cream represents a promising alternative to traditional antibiotics capable of treating common bacterial skin infections, such as impetigo. Formaldehyde could therefore help to combat antibiotic resistance by treating infections with antibiotic resistant bacteria (such as MRSA). In addition, formaldehyde could help combat antibiotic resistance by reducing the use of traditional antibiotics. For example, in scabies, a permethrin cream with a formaldehyde preservative would be sufficient in treating both the scabies and the associated bacterial infections, rather than using a permethrin cream for the scabies and an antibiotic for the secondary bacterial infections. More current and in-depth research is required into how formaldehyde affects humans after dermal application, the rate of absorption through 
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the skin and whether or not dermally applied formaldehyde can release dangerous levels of airborne formaldehyde before it can be used clinically as an alternative to conventional antibiotic therapy. This is beyond the scope of this thesis. However, the potential for formaldehyde to reduce the impact of antibiotic resistant bacteria is promising. 
4.2 Studies on Methicillin Sensitive and Methicillin Resistant Strains of S. aureus 
Staphylococcus aureus is a common cause of infectious disease in hospitals and the community. There exist strains of S. aureus resistant to many common antibiotics that are of particular concern including methicillin resistant S. aureus. The genetic changes that lead to methicillin resistance are well understood but changes to other parts of the cell are not as well characterized. Therefore, this study aimed to identify any differences in the cell membrane, protein profile, cell wall and surface charge of MRSA compared to MSSA. This included several prominent Australian strains as a focus. The differences found between these strains are unique to this study. An increased understanding of these cellular components and how they are altered in resistance would assist in understanding resistance mechanisms in S. aureus. It would also help to identify what may serve as a better cell target when treating infections with these bacteria or developing novel antimicrobial compounds that work against them. 
4.2.1 Cell Membrane Lipids The membrane layer in bacteria acts as a selectively permeable barrier to maintain appropriate concentrations of nutrients and waste inside the cell as well as to protect the cell from the entry of harmful substances such as antibiotics (7). The membrane itself is a phospholipid bilayer made up of a variety of different classes of phospholipids and glycolipids including phosphatidylglycerols, lysyl-phosphatidylglycerols, monoglycosyldiacylglycerols, diglycosyldiacylglycerols and cardiolipins. It is also known that the makeup of the bacterial cell membrane can change in response to external stimuli such as environmental stress or antibiotic presence. Therefore, this study aimed to identify any differences in the lipid species present in the membranes of methicillin resistant and methicillin sensitive strains of S. aureus. In this study, 22 lipid species were identified in all ten strains of S. aureus and of these, three were found to be present at significantly different abundances between the MSSA group and MRSA group. The significantly different species were a DGDG (DGDG (34:0)) and two Lys-PG’s (Lys-PG (32:0) and Lys-PG (38:0)). All three of these lipid species had a higher average abundance in the MSSA group compared to the MRSA group. Lipids in the class DGDG, along with MGDG lipids, are responsible for maintaining fluidity and stability of the membrane. A higher abundance of one DGDG with no clear change in MGDG means that the fluidity of the sensitive strains may be different than the resistant strains. Lipids in the class Lys-PG contribute a positive charge to the membrane to counterbalance the negative charge contributed by the cell wall and negatively charged membrane lipids such as PG. Therefore, a higher abundance of the positively charged Lys-PG with no apparent change in the negatively charged lipids indicates that the membrane of the sensitive strains may be more positively charged than the resistant strains. 
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This study is limited in that the lipid identification was done manually. If an automated process could be utilised, a wider variety of lipid species may have been detected along with any differences between the MSSA group and the MRSA group. The success of such an approach can be seen in Hewelt-Belka et al. (86). As lipid identification was conducted manually and subsequently the number of identified lipid species was limited, it is difficult to use the observed results to confidently claim that the membrane charge or fluidity was significantly altered between methicillin resistant and methicillin sensitive strains of S. aureus. However, this study does show that the lipid extraction process is effective and that there is some difference between the membrane lipids in S. 
aureus strains. There are examples in the literature of altered cell membranes in bacteria with resistance to membrane-targeting antibiotics. Daptomycin is an example of such an antibiotic. It forms a complex with calcium that oligomerises to form micelles that penetrate the cell wall and disrupt the lipid membrane (11,105). There are cases of bacteria developing daptomycin non-susceptibility and alterations to the cell membrane have been reported to play a role in this. Increases in the levels of Lys-PG in daptomycin non-susceptible strains of S. aureus have been reported in the literature as a result of gain-of-function mutations in mprF (106). In addition, other genes involved with lipid synthesis have been shown to be mutated in daptomycin non-susceptible S. aureus including CL synthases (cls) and PG synthase (pgsA) (107). The lipid extraction technique described here could therefore be used in future experiments to determine whether resistance to antibiotics other than methicillin is associated with an altered cell membrane phenotype. It could also be used to further characterise the changes between membrane lipids in methicillin sensitive and methicillin resistant strains of S. aureus. Both would benefit from the lipid analysis procedure being automated in some way. Finally, by characterising the specific lipid membrane makeup of antibiotic resistant strains it may become possible to better tailor antibacterial treatment to be more effective. For example, if a particular strain has a lower amount of positively charged lipids (such as Lys-PG) it may be more susceptible to CAMPs and thus these may be a better treatment method. 
4.2.2 Protein Content Methicillin resistance is caused by the presence of PBP2A (25). However other proteins may also be altered in abundance between methicillin sensitive and methicillin resistant strains of S. aureus. Protein abundances were therefore determined for each strain investigated in this study and compared. The proteins present at significantly different abundances between the MSSA group and MRSA group were limited with a few more different between the strains themselves. The proteins identified as being present at significantly different abundances played roles in protein synthesis, carbohydrate metabolism, amino acid metabolism and virulence. 
4.2.2.1 Differences in Protein Abundance Between MSSA Group and MRSA Group The proteins found at significantly different abundances between the MSSA group and MRSA group can be summarised into two categories based on their function. These are proteins used in protein synthesis and proteins used in metabolism. 
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The proteins present at a higher abundance in the MSSA group are polyribonucleotide nucleotidyltransferase, proline-tRNA ligase, formimidoylglutamase and 6-phospho- beta-galactosidase. These proteins are involved in the synthesis of proteins and the metabolism of amino acids and lactose. Polyribonucleotide nucleotidyltransferase (also known as PNPase) is responsible for the breakdown of mRNA. Its function has also been reported to play a role as a virulence factor by allowing S. aureus to survive in cold environments by the cold shock response (108,109). Furthermore, PNPase and the conserved virulence factor A have been suggested to competitively regulate RNA degradation in haemolysin production (110). Seeing this protein in a higher abundance suggests that the sensitive strains are better suited to cold environments and may produce less haemolysin. Proline-tRNA ligase is the aminoacyl tRNA synthetase responsible for attaching proline to its tRNA. Aminoacyl tRNA synthetases are essential for the synthesis of proteins as they prime tRNA, making them ready to contribute amino acids to the growing peptide chain. As such they have been suggested as a potential antibacterial drug target (111). The higher presence of proline-tRNA ligase in the sensitive strains may suggest it would act as a more effective antibacterial target in MSSA than in MRSA. Formimidoylglutamase plays a role in histidine biosynthesis and the degradation of amino acids (109) and 6-phospho-beta-galactosidase plays a role in galactose metabolism, breaking down lactose to galactose and glucose and is therefore used in energy production. Higher abundances suggest increased degradation of amino acids and utilisation of lactose. The proteins present at a higher abundance in the MRSA group are translation initiation factor IF-2, coenzyme A disulphide reductase, 50S ribosomal protein L16 and probable glycine dehydrogenase (decarboxylating) subunit 1. Translation initiation factor IF-2 is essential for protein synthesis through translation by interaction with the initiator fMet- tRNA, positioning it such that rate and fidelity of translation initiation is increased (112). A higher abundance of this protein suggests an increase in the synthesis of proteins. This is supported by the increase in the abundance of 50S ribosomal protein L16 as increased ribosome production is followed by increased translation (113). Coenzyme A disulphide reductase is an enzyme responsible for the reduction of coenzyme A. This is done to maintain redox balance in the cell and to protect the cell from reactive oxygen species. This enzyme has been highlighted as important in the growth and virulence of S. aureus (114). The higher abundance of this protein in the MRSA group suggests they are more virulent than the MSSA group and better protected from reactive oxygen species. Coenzyme A disulphide reductase is also a potential drug target and therefore drugs that target it may be better suited in the treatment of infections with resistant strains as it is present at higher abundances. The probable glycine dehydrogenase (decarboxylating) subunit 1 plays a role in the glycine cleavage system which is responsible for the degradation of glycine. A higher abundance in the resistant strains suggests a higher turnover of proteins. 
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4.2.2.2 Differences in Protein Abundance Between Strains The proteins found at significantly different abundances between the ten strains of S. 
aureus studied here can be summarised into three categories based on their function. These are proteins used in protein synthesis, proteins used as virulence factors and proteins used in metabolism. The 50S ribosomal protein L10 is present at a higher abundance in MSSA 4 and MRSA 9 and the 50S ribosomal protein L16 protein is present at a higher abundance in MRSA 9 when compared to the other strains. These proteins are essential for the synthesis of proteins and (as mentioned above) an increase in them is associated with an increase in protein production (113). Therefore, the synthesis of proteins may be increased in these strains. The same proteins are present at a lower abundance in MSSA 6 and MRSA 13. These strains may therefore have a decreased synthesis of proteins. The translation initiation factor IF-2, lysine-tRNA ligase, coenzyme A disulphide reductase and probable glycine dehydrogenase (decarboxylating) subunit 1 are all present at a higher abundance in MRSA 1 and MRSA 8. The same proteins are however present at a lower abundance in MRSA 2. Translation initiator factor IF-2 and lysine- tRNA ligase are both associated with protein synthesis (111,112). An increase of both indicates an increase in protein synthesis. Coenzyme A disulphide reductase is responsible for maintaining redox balance and allowing survival in the presence of reactive oxygen species. It is important for the growth, survival and virulence of S. 
aureus (114). Therefore, an increase suggests an increase in survivability and virulence. Superoxide dismutase [Mn/Fe] 1 is however present at a lower abundance in MRSA 8. This protein is also responsible for protection from superoxide radicals. It may be that the increase in coenzyme A disulphide reductase is sufficient for survival in this strain and therefore the increased synthesis of superoxide dismutase is unnecessary. However, in MRSA 2, superoxide dismutase is found at typical levels. Combined with the decrease in coenzyme A disulphide reductase, MRSA 2 may therefore be more susceptible to superoxide radicals. Similarly, MRSA 13 has a lower abundance of superoxide dismutase but a typical level of coenzyme A disulphide reductase suggesting increased susceptibility to superoxide radicals as well. Bone sialoprotein-binding protein is associated with staphylococcal osteomyelitis and arthritis as it is needed for binding to osteoblasts (115). It is present at a higher abundance in MRSA 9 but in MRSA 8 it has a lower abundance. This suggests that MRSA 9 may be better suited to causing staphylococcal osteomyelitis and arthritis while MRSA 8 is less suited to these infections. Zinc metalloproteinase aureolysin is present at a higher abundance in MRSA 2 and MRSA 9. This protein is a virulence factor that plays a role in allowing S. aureus to evade killing by neutrophils (116). Therefore, a higher abundance suggests that MRSA 2 and MRSA 9 are better suited to survive in human hosts and therefore cause infection. Conserved virulence factor C is present at a lower abundance in MSSA 4. This virulence factor is essential for the generation of haemolysin (110). Therefore, MSSA 4 may produce less haemolysin than the other strains studied here. It cannot be concluded that this strain is less virulent however as it produces average levels of the other virulence 
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factors described here and produces a higher amount of staphylococcal secretory antigen ssaA2. Staphylococcal secretory antigen ssaA2 is also present at higher abundances in MSSA 2, MRSA 2 and MRSA 9. The function of this protein is however unknown. ESAT-6 secretion system extracellular protein A is present at a slightly lower abundance in MSSA 6 and MRSA 8. The remaining strains all exhibit similar levels of expression. This protein is required for the pathogenesis of S. aureus infections (117). The limited difference between strains is therefore expected as all studied strains are capable of infecting humans and hence this protein is needed. Glutamine synthetase is present at a significantly higher abundance in MSSA 4 and MRSA 9. Glutamine synthetase plays multiple roles including as an enzyme, a transcription coregulator and in the regulation of genes in nitrogen metabolism. Inactivation of the femC locus in S. aureus is known to reduce methicillin resistance. This is through a Tn551 insertion in glnR that results in reduced glutamine synthetase activity and hence reduced glutamine in cells. Low glutamine concentration results in a reduced amidation of the iso-D-glutamate in the peptidoglycan stem pentapeptide. It is hypothesised that this serves as a suboptimal substrate to PBP2A hence reducing methicillin resistance (118). An increased abundance of glutamine synthetase in MSSA 4 and MRSA 9 may therefore result in increased glutamine and hence slightly higher methicillin resistance. This is unexpected in MSSA 4 but the increase may not be enough to categorise the strain as methicillin resistant. It may only be more tolerant than other methicillin sensitive strains. 6-phospho-beta-galactosidase is present at a higher abundance in MSSA 6 and MSSA 8 and a lower abundance in MRSA 8, MRSA 9 and MRSA 13 suggesting increased utilisation of lactose in MSSA 6 and MSSA 8 and decreased utilisation in MRSA 8, MRSA 9 and MRSA 13. NAD-specific glutamate dehydrogenase is present at a higher abundance in MRSA 9 and a lower abundance in MSSA 2 and MRSA 8. This protein plays an essential role due to the importance of glutamate and 2-oxoglutarate in nitrogen and carbon compound metabolism (119). Hence the utilisation of these compounds may be increased in MRSA 9 and decreased in MSSA 2 and MRSA 8. The results presented here highlight that there are differences in the abundance of proteins between methicillin sensitive and methicillin resistant strains besides those that determine methicillin resistance. Furthermore, even within the MSSA group and MRSA group there can be a large difference in the abundance of different proteins between strains. This brings to attention the benefit of a deeper understanding of differences between strains. Bacterial proteins are being investigated for their potential as novel drug targets (120). A deeper understanding of the proteins present and their abundance in clinically relevant strains would allow for better targeted prescription of these novel drugs. Different strains would be affected more or less depending on the target protein being more or less abundant. Therefore, in addition to developing antibiotics that target these proteins, better characterisation of protein changes in different antibiotic resistant strains is needed to better tailor antimicrobial therapy. The increasing prevalence of UPLC-MS will assist in this. As would the generation of 
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databases that characterise not only antibiotic resistance of each strain but also alterations in protein abundances. In addition to understanding the differences in protein abundances between strains, future studies could also be directed towards investigating protein profiles after exposure to stresses. This could include antibiotic exposure or environmental stresses such as temperature and salinity. This would help to understand how clinically relevant strains react in response to antibiotics and stress and whether or not his could help in treating infections. Some past studies have already begun to do this including El-Rami et al. (121) that investigated the effect of ampicillin on protein expression in Streptococcus 
sanguinis and Tavares et al. (122) that investigated the effect of temperature on protein expression in Streptococcus agalactiae. 
4.2.3 Cell Wall Thickness The cell wall of Gram-positive bacteria is responsible for maintaining cell shape and assisting in resisting osmotic pressure. In staphylococci the cell wall is reported to range from 20 nm to 40 nm in thickness (53). This is consistent with the results presented in this study with no cell wall thickness observed to be below 20 nm and none above 32 nm. Methicillin resistance is due to the acquisition of the mecA gene present on SCCmec. This gene encodes the protein PBP2A that is able to continue cell wall synthesis even in the presence of methicillin (25). This alteration to the cell wall synthesis machinery may have an impact on the cell wall structure and so the thickness of the cell walls of five methicillin sensitive and five methicillin resistant strains of S. aureus were measured and compared both individually and as the MSSA group and the MRSA group. Interestingly the MSSA group had both the strain with the thinnest cell wall (MSSA 2) and the strain with the thickest cell wall (MSSA 6). The cell walls of the methicillin resistant strains were more closely clustered together. 
First an ANOVA was conducted at a significance of p ≤ 0.05 looking for any significant difference between the cell wall thickness of all ten strains. The cell wall of the MSSA 6 strain was significantly thicker than the cell wall of three MSSA strains and three MRSA strains and was therefore the most different followed by MSSA 2 which had a cell wall that was significantly thinner than two MSSA and two MRSA strains. The cell wall of MRSA 9 was significantly thicker than the cell wall of MRSA 8. The differences in cell wall thickness described here are unlikely to be due to antibiotic resistance as MSSA 2 was thinner than an equal number of MSSA and MRSA strains and MSSA 6 was thicker than an equal number of MSSA and MRSA strains. Furthermore, MRSA 9 was thicker than another MRSA strain rather than an MSSA strain. After identifying the significant differences in the cell wall thickness of individual strain pairs, the strains were then divided into the MSSA group and MRSA group and the average cell wall thickness for each group determined. A Welch Two Sample t-test was conducted in R at a significance of p ≤ 0.05 looking for any significant difference between the cell wall thickness of these two groups. As the calculated p-value of 0.9502 was more than 0.05 it was concluded that there was no significant difference between the cell wall thickness of the MSSA group and MRSA group. 
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There are three potential explanations for the lack of any significant differences between the cell wall thickness of these two groups of S. aureus. The first is that as the cells were grown in the absence of methicillin, the mecA gene may not have been activated resulting in the native cell wall synthesis machinery being used in the methicillin resistant strains rather than PBP2A. This would result in no difference in the synthesis and hence thickness of the cell wall. This is supported by the lack of PBP2A identified by UPLC-MS. The second potential reason for a lack of significant difference is the comparison of strains based on antibiotic susceptibility rather than genetic difference. For example, rather than using five strains of MSSA and five unrelated MRSA strains, methicillin sensitive strains could have been repeatedly exposed to sublethal concentrations of methicillin until resistance to that antibiotic developed. If the cell wall thickness of this new resistant strain was compared against the sensitive strain it evolved from there would be a better chance of observing the effect (if any) of this resistance on the structure of the cell wall. This method has been used in prior studies including in Yuan et al. (123) (which identified cell wall thickening in strains resistant to amikacin) and Camargo et al. (124) (which identified cell wall thickening in strains resistant to daptomycin). Finally, the reason for a lack of observed difference in cell wall thickness between the strains studied is simply due to the absence of any difference. However, without testing the two above hypotheses in subsequent experiments it cannot be definitively concluded that this is the case. 
4.2.3.1 Improvements in Methodology While unable to make a conclusion about the difference in cell wall thickness in MSSA and MRSA strains, the work presented here does serve to provide information that could be beneficial in improving the methodology and overcoming the difficulties associated with the bacterial cell resin embedding protocol, the sectioning of resin blocks containing bacterial cells using an ultramicrotome and imaging the resin sections under STEM. Available articles that use these methods do not go into much detail with the specifics of successfully embedding bacteria and thus the following information may be beneficial for others who wish to use the methods presented here. 
4.2.3.1.1 Improvements in Resin Embedding As mentioned in the methods section, initial experiments did not contain the acetone dehydration step. This resulted in brittle samples and so an acetone dehydration step was included in subsequent experiments. The rationale behind the inclusion of the acetone step is detailed in Santhana et al. (125). In brief, acetone is described as being able to be boiled off at 60 °C (the temperature used to polymerise and harden the resin blocks) whereas ethanol cannot. If ethanol remains in the resin while it is polymerising, it is capable of inhibiting resin polymerisation causing the block to remain softer and therefore harder to section. The acetone dehydration step solves this problem. After the 
acetone dehydration step of the resin embedding protocol, 10 µL of the suspension was added to the resin which was then polymerised overnight at 60 °C in the initial experiments. After hardening however, it was impossible to determine if the cells were present in the resin block as they were not visible to the unaided eye. This made it difficult to section on an ultramicrotome as there was no way to tell if the cells had been sectioned successfully and were present in the resin slices. Subsequent tests altered this 
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step and instead of taking a volume of cell suspension, the suspension was again centrifuged and the cells taken directly from the cell pellet using an inoculating loop which was then streaked into the resin before overnight polymerisation at 60 °C. It was also important that a large initial inoculum was used before subjecting the sample to fixing and dehydrating. This ensured there was enough cells to be streaked into the resin and still remain visible. It also assisted with not losing cells as there were many steps that required removal of a supernatant which if the cell pellet was too small could result in accidental pipetting of the cells as well. When both of these steps were used, the cells were visible as black specks in the resin block allowing for ease of confirmation when embedding and sectioning. 
4.2.3.1.2 Improvements in Sectioning of Resin Blocks Initial experiments used a flat silicone mould. Resin blocks set in this were then removed and stored in a plastic specimen container at room temperature before sectioning. These samples were however brittle and shattered during sectioning even with the inclusion of the acetone dehydration step. This was most likely due to the resin block absorbing moisture from the air. Subsequent tests used a vertical plastic micromould that forced the cells to settle at the bottom. The blocks were then left in the mould until sectioning. The use of these vertical plastic micromoulds had two major benefits. The first was, by keeping the resin block in the mould, the top of the block was the only part exposed to the environment, protecting the bottom part of the resin block, containing the cells, from moisture and preventing the face that would be sectioned from becoming brittle. The second benefit was that by standing vertically, gravity forced the cells to settle at the bottom of the resin block while hardening allowing for sections containing the cells themselves to be cut more easily as they were present closer to the face of the block that was cut. No trimming of the block was required. 
4.2.3.1.3 Improvements in Imaging Resin Slices When imaging the cells using STEM, the electron beam (at a voltage of 30 kV) was capable of penetrating through and tearing the resin slice, destroying the sample before images could be taken. In order to prevent this a lower beam voltage was tried with no appreciable difference in sample destruction observed. A smaller aperture size was also 
tried (down from 30 µm to 20 µm) similarly with no major improvement. The best solution was to image cells that were located close to the copper grid itself as the copper would absorb much of the charge, protecting the resin slice and allowing for successful imaging. It is therefore recommended that multiple sections are made per sample to give a greater chance that the samples will contain enough cells close to the copper grid for successful imaging of a sufficient number of cells. 
4.2.4 Whole-Cell Surface Charge The net cell surface charge in Gram-positive bacteria is negative due to the teichoic acids present in the cell wall. To compare the whole-cell surface charge between the ten strains used in this study, a cytochrome c binding assay was used. Cytochrome c is a cationic protein with a high affinity for negatively charged cells. Therefore, the higher the negative charge the more cytochrome c will bind (92). The percent bound cytochrome c and hence the negative charge did not vary that much between the ten strains. What little variation is present between strains was not significant as was 
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confirmed by a one-way ANOVA with a calculated p-value of 0.875. In addition to the percent bound cytochrome c of each individual strain the percent bound cytochrome c of the MSSA group and MRSA group was determined. A Welch Two Sample t-test calculated a p-value of 0.3437 meaning there was no significant difference in the percent bound cytochrome c between these two groups and hence no significant difference in whole-cell surface charge. Bacterial cell surface charge is known to affect susceptibility to CAMPs (91). In addition, daptomycin resistance has been associated with an increased synthesis of teichoic acids (and hence decreased cell surface charge) (1). While no significant difference in cell surface charge was detected between the ten strains studied here, past work has identified mutations in S. aureus that has been responsible for altering whole-cell surface charge and affecting antibiotic susceptibility. For example, Cui et al. (126) identified a decreased negative charge in strains of S. aureus resistant to daptomycin and vancomycin. In Meehl et al. (92), mutations in graRS and vraFG in S. aureus led to increased susceptibility to vancomycin and a more negative net surface charge. It is possible that the reason for a lack of significant difference in cell surface charge in this study is the lack of antibiotic challenge. As the strains tested in this experiment were not subject to exposure to any charged antimicrobials, they did not have the need to alter their cell surface charge to survive. Alternatively, an alteration to cell surface charge may not have been beneficial in resistance to methicillin and so was not developed in MRSA strains. This is supported by methicillin being a non-charged molecule. Alterations to the bacterial surface charge would most likely not have a profound effect on susceptibility to it. Future experiments would benefit from including a treatment of some charged molecule with antimicrobial properties to identify if exposure to sublethal concentrations can induce changes in the whole-cell surface charge leading up to and including resistance. 
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5. Conclusion Antibiotic resistance has become a serious threat to human health with many human pathogens having developed resistance to commonly used antibiotics. Of particular concern are methicillin resistant strains of S. aureus. The rate of antibiotic resistance development has outpaced the rate of development of antibiotics leading to strains of bacteria resistant to all currently used antibiotics. Without the development of new antibacterial treatments that bacteria cannot develop resistance to, we may see the start of the post antibiotic era. To address this issue, the anti-scabies medication permethrin and the preservative formaldehyde were investigated both alone and in combination to identify whether or not they were suitable for treatment of antibiotic resistant bacterial infections, particularly those of methicillin resistant S. aureus. This allowed for the identification of formaldehyde as a potential alternative treatment for antibiotic resistance bacterial infections. This study showed that permethrin is a poor antimicrobial whereas formaldehyde is able to exert rapid killing of both methicillin sensitive and methicillin resistant S. aureus both in the presence and absence of permethrin. Formaldehyde at concentrations as low as 0.07% was capable of completely inhibiting the growth of S. aureus. Furthermore, at a concentration of 0.3% that is present in the permethrin cream, it was able to inhibit all growth upon contact. This was observed both alone and in the presence of permethrin. This means that formaldehyde may represent an alternative to conventional antibiotics for treating bacterial skin infections. Before formaldehyde can be recommended for use in this manner the harmful side effects of formaldehyde use in humans need to be considered. This is made difficult by the limited information regarding the effect of dermal application of formaldehyde. While airborne formaldehyde is known to cause nasopharyngeal cancer, significantly less is known about the harmful effects of formaldehyde after dermal application. What information is available however seems to indicate that formaldehyde is not absorbed readily through skin and what little is absorbed is detoxified to formate. Formaldehyde is therefore likely to be minimally harmful in humans. This is supported by its common use as a preservative in cosmetics and medicinal creams. Further research into these effects would be reassuring however. In addition to identifying the effects of permethrin and formaldehyde on S. aureus, the ultrastructure and physiology of methicillin sensitive and methicillin resistant strains of 
S. aureus were analysed and compared. This was done in an attempt to identify how they may change during the development of resistance. In doing so a deeper understanding of these changes was gained as was a deeper insight into the methodology used to investigate these structures. This was done with a focus on the cell wall, cell surface charge and lipid and protein profiles of the bacteria. This study identified minimal differences between the abundance of cell membrane lipids in the MSSA group and the MRSA group. The lipids present at significantly different abundances between the MSSA group and the MRSA group included one DGDG and two Lys-PGs. The reason for the limited identified difference may have been due to 
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the lack of antibiotic challenge, the strains compared not being genetically related and/or identification of lipids done manually rather than through an automated system. This study also identified eight proteins that were present at significantly different abundances between the MSSA group and MRSA group and 18 proteins that were present at significantly different abundances between the individual strains. These proteins played roles in protein synthesis, carbohydrate metabolism, amino acid metabolism and virulence. This showed that there are differences in protein expression between individual strains beyond resistance mechanisms and shows the potential for better tailoring of antibacterial therapy. This study identified differences between the cell wall thickness of individual strains of 
S. aureus but not between the MSSA group and MRSA resistant group. But as the differences were not specific to resistant or sensitive strains it is most likely unrelated to methicillin resistance. The work here did identify protocol improvements for sample preparation for scanning transmission electron microscopy that would be beneficial to researchers including the use of an acetone dehydration step, direct streaking of bacteria into unhardened resin, use of large inoculum, use of vertical plastic micromoulds and imaging cells close to copper grids to prevent puncturing of resin. Finally, no difference in the whole-cell surface charge between methicillin sensitive and methicillin resistant S. aureus was identified in the study. The lack of antibiotic challenge or alterations to charge not benefiting methicillin resistant bacteria may have been responsible for this. In summary, while permethrin is a poor inhibitor of bacterial growth, formaldehyde may serve as an alternative to conventional antibiotics. However, its use cannot be recommended without further research into its effects after dermal application. Furthermore, there are differences between the membrane lipids, protein profile and cell wall thickness in different strains of S. aureus. A deeper understanding of these differences may lead to the discovery of new antibacterial targets, as well as the development of more effective treatment regiments. 
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6. Future Studies The work presented here has identified that formaldehyde has the potential to work as an alternative to traditional antibiotics. However, there is a lack of information regarding its effects when applied dermally. In order to address this gap in research, work should be conducted on the effect that small concentrations of formaldehyde have after dermal contact. This should be done with a focus on irritation, development of allergy, development of cancer and any effects of prolonged use. Ideally this would eventually be conducted in humans with the minimal harmful concentration identified. If, after this work is completed, formaldehyde is confirmed to be minimally harmful, it could then be recommended for use by itself for treating bacterial skin infections. This would represent a cheaper option and would be particularly useful in cases where traditional antibiotics have failed (such as refractory impetigo). If used in this way it also has the potential to reduce the use of antibiotics, such as in the treatment of scabies and the accompanying secondary bacterial infections. Rather than a cream to treat the scabies infection and an antibiotic to treat the bacterial infections, a single permethrin cream with a formaldehyde preservative would be sufficient. The use of formaldehyde as an alternative treatment would not only help combat antibiotic resistance by treating the infections, it would also help by reducing the prevalence of antibiotic resistant strains. This would be done by reducing the use of conventional antibiotics and hence lessening the selection pressure that promotes the development and spread of antibiotic resistant strains of bacteria. The work presented here also presents new differences between strains of methicillin sensitive and methicillin resistant S. aureus beyond the well characterised synthesis of penicillin binding protein 2A in MRSA. Furthermore, it shows that there are differences between strains. This brings to attention the importance of characterising these differences. Future work should then be conducted to better characterise the differences between individual strains. This could lead to the identification of targetable characteristics for new antibacterial treatments. Alternatively, characteristics that make particular treatments more or less effective can be identified in order to better tailor antimicrobial therapy to specific strains. This research should be conducted with a focus on different but genetically related strains to better characterise how resistance alters the cell. These strains should also be investigated after exposure to stresses such as temperature and antibacterial challenge to understand how they change in these environments. 
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8. Appendix 
Table 15: Strain pairs of S. aureus with fold change of protein abundances ≥ 2. S=MSSA, R=MRSA.  
UniProt 
Accession 
Number 
Strain Pairs and Fold Change 
A5ISF8 R1/R8 - 4.008 S1/R8 – 5.046 S8/R8 – 7.726 S2/R13 – 2.607 
 R2/R8 - 4.209 S2/R8 – 5.754 S6/R9 – 2.193 S4/R13 – 2.705 
 R9/R8 - 3.321 S4/R8 – 5.972 S8/R9 – 2.327 S6/R13 – 3.298 
 R13/R8 - 2.207 S6/R8 – 7.281 S1/R13 – 2.286 S8/R13 – 3.500 A5IQ93 R9/R1 – 2.410 R2/R13 – 2.727 R1/S1 – 2.615 S4/S1 – 4.014 
 R9/R2 – 2.528 R8/R13 – 2.393 R2/S1 – 2.493 R1/S2 – 2.886 
 R9/R8 – 2.881 R9/R13 – 6.894 R8/S1 – 2.188 R2/S2 – 2.751 
 R1/R13 – 2.860 S4/R13 – 4.391 R9/S1 – 6.303 R8/S2 – 2.414 
 R9/S2 – 6.955 R2/S6 – 2.297 S4/S6 – 3.699 S4/S8 – 2.464 
 S4/S2 – 4.429 R8/S6 – 2.016 R9/S8 – 3.868 R9/S6 – 5.808 
 R1/S6 – 2.410    A5ISE7 R9/R1 – 3.243 R13/R8 –17.673 S4/R9 – 13.115 S2/S6 – 19.212 
 R13/R1 - 29.549 S1/R8 – 33.212 S8/R9 – 2.867 S4/S6 – 9.661 
 S1/R1 – 55.529 S2/R8 – 50.581 S2/R13 – 2.862 S8/S6 – 1.112 
 S2/R1 – 84.570 S4/R8 – 25.436 R13/S6 – 6.713 R13/S8 – 3.178 
 S4/R1 – 42.528 S6/R8 – 2.633 S1/S6 – 12.615 S1/S8 – 5.972 
 R13/R2 - 15.499 S8/R8 – 5.561 S4/R2 – 22.306 S2/S8 – 9.096 
 S1/R2 – 29.125 R13/R9 – 9.113 S2/R9 – 26.080 S4/S8 – 4.574 
 S2/R2 – 44.357 S1/R9 – 17.124   A5ISF3 R1/R2 – 6.148 R1/R9 – 2.207 R1/S2 – 4.479 R1/S6 – 4.811 
 R8/R2 – 5.159 R1/R13 – 2.603 R8/S2 – 3.758 R8/S6 – 4.037 
 R9/R2 – 2.786 R8/R13 – 2.184 R9/S2 – 2.029 R9/S6 – 2.180 
 R13/R2 – 2.362 R1/S1 – 2.865 R1/ S4 – 3.823 R1/S8 – 6.824 
 S1/R2 – 2.145 R8/S1 – 2.405 R8/S4 – 3.208 R8/S8 – 5.727 
 S1/S8 – 2.382 R13/S8 – 2.622 R9/S8 – 3.092  A7WYS8 R1/R2 – 4.400 R1/R13 – 2.865 R8/S2 – 2.952 R1/S8 – 6.365 
 R8/R2 – 3.768 R8/R13 – 2.454 S4/S2 – 2.326 R8/S8 – 5.452 
 S4/R2 – 2.969 R1/S1 – 2.658 R1/S6 – 4.978 R9/S8 – 2.293 
 R1/R9 – 2.776 R8/S1 – 2.277 R8/S6 – 4.264 R13/S8 – 2.221 
 R8/R9 – 2.378 R1/S2 – 3.446 S4/S6 – 3.360 S1/S8 – 2.394 
 S4/S8 – 4.296    A5IV27 R9/R1 – 4.073 R8/R13 – 2.430 R9/S1 – 4.799 R2/S6- 7.346 
 R9/R2 – 3.398 R9/R13- 13.861 R9/S2 – 6.271 R8/S6 – 4.375 
 R9/R8 – 5.705 S1/R13 – 2.888 R9/S4 – 3.733 R9/S6 – 24.960 
 R1/R13 – 3.403 S2/R13 – 2.210 R1/S6 – 6.128 S1/S6 – 5.201 
 R2/R13 – 4.079 S4/R13 – 3.714 S4/S6 – 6.687 S2/S6 – 3.980 
 R2/S8 – 2.111 S8/S6 – 3.480 R9/S8 – 7.173  Q6GEA1 S6/R1 – 2.069 R13/R8 – 5.028 S8/R8 – 17.622 S6/R9 – 3.837 
 S8/R1 – 2.452 S1/R8 – 14.163 R2/R9 – 3.158 S8/R9 – 4.546 
 R1/R8 – 7.197 S2/R8 – 7.073 S1/R9 – 3.654 R2/R13 – 2.435 
 R2/R8 – 12.241 S4/R8 – 8.945 S4/R9 – 2.308 S1/R13 – 2.817 
 R9/R8 – 3.876 S6/R8 – 14.872 S8/R13 – 3.505 S6/R13 – 2.958 
 S1/S2 – 2.002 S6/S2 – 2.103 S8/S2 – 2.492  P0A039 R9/R1 – 6.842 R2/R13 – 2.385 S4/S1 – 6.061 R8/S6 – 2.961 
 S4/R1 – 4.320 R8/R13 – 2.774 S4/S2 – 5.506 R9/S6 – 14.887 
 R9/R2 – 5.847 R9/R13- 13.945 R1/S6 – 2.176 S4/S6 – 9.399 
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 S4/R2 – 3.691 S4/R13 – 8.804 R2/S6 – 2.546 R2/S8 – 2.235 R9/R8 – 5.027 R9/S1 – 9.600 S4/S8 – 8.250 R8/S8 – 2.599 S4/R8 – 3.174 R9/S8 – 13.067 R1/R13 – 2.038  Q6GIB7 R1/R2 – 7.130 R8/R9 – 2.218 R8/S2 – 3.898 R1/S8 – 8.293 
 R8/R2 – 5.293 R1/R13 – 3.556 R1/S4 – 3.654 R8/S8 – 6.157 
 R9/R2 – 2.386 R8/R13 – 2.640 R8/S4 – 2.713 R9/S8 – 2.776 
 R13/R2 – 2.005 R1/S1 – 2.673 R1/S6 – 5.436 R13/S8 – 2.332 
 S1/R2 – 2.667 R1/S2 – 5.251 R8/S6 – 4.036 S1/S8 – 3.102 
 R1/R9 – 2.988 S4/S8 – 2.270 S1/S6 – 2.034  A5IUX8 S6/R1 – 2.179 S6/R8 – 21.642 R2/R13 – 3.771 R2/S2 – 2.364 
 S8/R1 – 2.346 S8/R8 – 23.299 S1/R13 – 2.194 S6/S2 – 5.068 
 S6/R2 – 2.144 R1/R9 – 3.737 S4/R13 – 2.205 S8/S2 – 5.456 
 S8/R2 – 2.308 R2/R9 – 3.798 S6/R13 – 8.084 S6/S4 – 3.666 
 R1/R8 – 9.933 S1/R9 – 2.210 S8/R13 – 8.703 S8/S4 – 3.947 
 R2/R8 – 10.094 S4/R9 – 2.221 S6/S1 – 3.685 S1/R8 – 5.873 
 R9/R8 – 2.658 S6/R9 – 8.142 S8/S1 – 3.967 S2/R8 – 4.271 
 R13/R8 – 2.677 S8/R9 – 8.766 R1/S2 – 2.326 S4/R8 – 5.903 
 R1/R13 – 3.711    A5IT64 R1/R2 – 5.249 R8/S1 – 2.973 R9/S6 – 4.060 R9/S8 – 5.124 
 R8/R2 – 10.128 R8/S2 – 3.522 R13/S6 – 2.793 R13/S8 – 3.525 
 R9/R2 – 2.761 R1/S4 – 3.463 S1/S6 – 5.009 S1/S8 – 6.321 
 S1/R2 – 3.407 R8/S4 – 6.684 S2/S6 – 4.228 S2/S8 – 5.336 
 S2/R2 – 2.876 S1/S4 – 2.248 S4/S6 – 2.228 S4/S8 – 2.812 
 R8/R9 – 3.668 R1/S6 – 7.718 R1/S8 – 9.739 R8/S8 – 18.793 
 R1/R13 – 2.763 R8/S6 – 14.893   Q5HHC7 R9/R1 – 4.021 S4/R8 – 2.400 R9/S2 – 6.818 R9/S6 – 3.569 
 R9/R2 – 2.847 R9/R13 – 2.720 R13/S2 – 2.507 R9/S8 – 5.630 
 R2/R8 – 2.185 R9/S1 – 4.863 S4/S2 – 2.630 R13/S8 – 2.070 
 R9/R8 – 6.221 R2/S2 – 2.395 R9/S4 – 2.592 S4/S8 – 2.172 
 R13/R8 – 2.287    Q2FYK3 R8/R2 – 2.053 R1/S4 – 8.198 R13/S4 - 14.514 S6/S4 – 9.483 
 R9/R2 – 2.148 R2/S4 – 7.034 S1/S4 – 9.549 S8/S4 – 10.643 
 R13/R2 – 2.063 R8/S4 – 14.438 S2/S4 – 12.373 R9/S4 – 15.111 P0A0J1 R1/R8 – 20.029 S2/R8 – 16.681 R1/R13 – 3.601 S2/R13 – 2.999 
 R2/R8 – 19.041 S4/R8 – 21.349 R2/R13 – 3.423 S4/R13 – 3.838 
 R9/R8 – 14.916 S6/R8 – 10.517 R9/R13 – 2.682 S8/R13 – 3.177 
 R13/R8 – 5.562 S8/R8 – 17.673 S1/R13 – 2.767 S4/S6 – 2.030 
 S1/R8 – 15.392    A0A0H2XI99 R1/R8 – 2.084 R1/S6 – 2.355 S1/S6 – 2.004  P81177 R9/R8 – 2.205 R9/R13 – 2.983 R2/S6 – 2.245 R2/S8 – 2.735 
 R2/R13 – 2.493 R9/S1 – 2.358 R9/S6 – 2.686 R9/S8 – 3.272 
 R9/S2 – 2.044    Q14U76 R9/R2 – 2.525 R9/R8 – 74.101 S1/R8 – 42.113 S4/R8 – 36.129 
 R1/R8 – 39.318 R13/R8 -32.652 S2/R8 – 29.661 S6/R8 – 43.930 
 R2/R8 – 29.345 S8/R8 – 49.142 R9/S4 – 2.051  Q2G2J2 R2/R1 – 5.732 S2/R8 – 8.174 R9/S1 – 9.728 R9/S6 – 14.201 
 R9/R1 – 15.214 S4/R8 – 3.998 S2/S1 – 4.811 S2/S6 – 7.023 
 S2/R1 – 7.524 R2/R13 – 6.453 S4/S1 – 2.353 S4/S6 – 3.435 
 S4/R1 – 3.680 R9/R13 - 17.130 R9/S2 – 2.022 R2/S8 – 5.118 
 R9/R2 – 2.654 S2/R13 – 8.471 R9/S4 – 4.134 R9/S8 – 13.586 
 R2/R8 – 6.227 S4/R13 – 4.143 S2/S4 – 2.044 S2/S8 – 6.719 
 R9/R8 – 16.528 R2/S1 – 3.665 R2/S6 – 5.350 S4/S8 – 3.286  
